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ABSTRACT 
Abnormalities in the electrical activity of cardiac and neuronal cells can cause 
serious pathologies that affect an increasing number of individuals. In the heart, 
dysfunctions in the autorhythmic activity of its natural pacemaker, the sinoatrial 
node (SAN), are becoming progressively more common due to population ageing 
and are currently treated with implantation of an electronic pacemaker. In the 
brain, a typical disorder due to neuron hyperexcitability is epilepsy, which is the 
third most common brain disorder.  
The first part of this thesis studied a cell-based method to generate a biological 
pacemaker, that is a cellular substrate able to drive the beating rate of the host 
tissue. Potentially, a biological pacemaker presents several advantages compared to 
electronic devices: it can respond to nervous system regulation and does not need 
maintenance or substitution. We adopted the strategy of stem cell differentiation to 
select early pacemaker precursors. As a selection marker, we used CD166, since it 
is transiently but specifically expressed in the SAN during embryonic development. 
Accordingly, here we show by immunofluorescence that CD166 is co-expressed 
with the SAN marker HCN4 in mouse forming heart at day 10.5. CD166-selected 
cells were previously shown to express SAN genes. In this study, we functionally 
characterized CD166-selected cells showing that they present morphological and 
electrophysiological characteristics of SAN cells, expressing functional HCN and 
calcium channels. They can respond to autonomic nervous system regulation: 
isoproterenol increases (+57%) and acetylcholine decreases (-23%) their firing rate. 
Importantly, they are also able to drive the rate of rat neonatal cardiomyocytes in 
co-culture, thus acting as a real pacemaker in vitro. We also set the foundations for 
translating this selection protocol to human cells, showing that CD166 is expressed 
during human induced pluripotent stem cell (hiPSC) cardiac differentiation.  
This study demonstrated that at early stages CD166 selects mouse pacemaker 
precursors that function as SAN-like cells in vitro. Moreover, it opens promising 
perspective for translating the method to hiPSCs, with the aim of generating 
patient-specific biological pacemakers.  
The second part of this thesis presents a study aimed at identifying genetic 
mutations in epileptic patient and assessing whether they may contribute to the 
phenotype, in order to provide new targets for pharmacological treatments. We 
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found M54T MiRP1 mutation in an epileptic patient and in her daughter. MiRP1 
was shown to act as β-subunit of HCN channels, whose alterations in the brain 
have been previously linked to the epileptogenic process. Moreover, the same 
M54T mutation has been recently found in a patient with long-QT and sinus 
bradycardia, causing a decrease of HCN4, but not of HCN2 current when 
expressed in neonatal rat cardiomyocytes. Therefore, we decided to evaluate 
whether M54T mutation was involved in excitability alterations proper of the 
epileptic disorder, acting on HCN channels. We firstly verify the effect of M54T 
mutation in CHO cells by co-expressing wild-type (WT) MiRP1, M54T mutant or 
both (WT/M54T) with either HCN2 or HCN4. Electrophysiological analysis shows 
that M54T mutation does not affect HCN2 or HCN4 voltage dependence and 
current densities. We observed a slower activation of HCN2 at -95 and -85 mV and 
a slower deactivation of HCN4 in the range of -25/-45 mV, however no difference 
were found at other voltages. Notably, no effect of WT MiRP1 on HCN2 or HCN4 
properties was observed. We then replicated the same co-transfection experiments 
in rat neonatal cortical neurons. Again, we found no difference in HCN2 or HCN4 
voltage dependence and current densities, but only a slower HCN2 activation at -
85 mV in M54T MiRP1 transfected neurons compared to control and WT. Finally, 
we assessed whether M54T mutation may alter neuronal excitability acting on 
other ion channels, by transfecting neurons with only WT or mutated MiRP1. We 
found that WT MiRP1 induced a two-fold decrease in the threshold of action 
potential firing and increased their rate, causing an overall increased cell 
excitability compared to control. This effect was reverted by M54T mutation.  
These data oppose a possible contribution of M54T mutation to the 
epileptogenesis and also rule against the previously acknowledged role of MiRP1 
in modulating HCN channels. 
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FOREWORD 
Rationale and relevance of the project 
My thesis project was part of a larger project, aimed at generating a biological 
pacemaker, in order to overcome the already discussed problems associated with 
electronic pacemakers. This is particularly important in sight of the increasing rate 
of electronic pacemaker implants11 likely due to the population ageing.  
We chose the strategy of cell therapy to attempt obtaining a biological pacemaker, 
focusing on cardiac differentiation of pluripotent stem cell, in order to obtain a 
cellular substrate able to pace other cells once inserted and integrated within the 
cardiac tissue. This cell-based method was preferred to the gene therapy previously 
adopted by others31,44,53,72,96, because it provides the generation of de novo 
pacemaker cells avoiding the genetic manipulation of resident cells. The idea is to 
select precursors during stem cell differentiation and assess their SAN-like 
characteristic in culture, verifying importantly the loss of teratogenic potential and 
the maintenance of the phenotype for long periods.  
The main challenge with this strategy is to find a selection method, since 
pacemaker cells upon ESC differentiation are interspersed among other cardiac 
cell types7. Importantly, in order to be suitable for future clinical applications, the 
selection method should avoid genomic modification of the selected cells.  
Previous data  
Evidences on CD166 expression during embryonic development make it a 
possible surface marker for early cardiomyocytes. Thus, the aim of this project was 
to evaluate whether CD166 expression could be used as a selection marker to 
isolate SAN progenitors from ESC-differentiating cardiomyocytes.  
Since cardiac expression of CD166 is restricted to a specific developmental stage 
(E8.5-10.5), the first part of the project focused in determining the best time-
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window for selecting SAN precursors from ESCs. After sorting CD166-positive and 
negative populations at different days (6, 8, 10 and 15) of in vitro differentiation, 
the expression of the cardiac marker α-actinin was assessed.  
As shown in figure 1, this analysis indicated day 8 as the time point associated with 
both a sufficient percentage of CD166+ cells and the highest expression in CD166+ 
cells of α-actinin.  At later days, even though the percentage of CD166+ cells 
increased, the cardiac specificity (α-actinin expression level) decreased. Flow 
cytometry analysis revealed that at day 8, only a very limited fraction of CD166+ 
population expressed markers of cardiovascular, mesenchymal or hematopoietic 
precursors, suggesting that CD166 may be a specific marker for cardiac-fated cells 
(Figure 2). Day 8 was then chosen as the best day to select SAN precursors. 
The second part of the project concerned the characterization of CD166+ cells by 
gene expression analysis. At the day of selection, they expressed higher levels of 
early cardiac-specific genes (cTnT, Mef2c, Gata4) compared to CD166- population  
Figure 1: CD166 recognizes cardiac precursors.   
Upper panel: representative dot plots of CD166
-
 and CD166
+
 populations (P2 and P3 gates, 
respectively) obtained by flow cytometry analysis of cells dissociated from embryoid bodies (P1 
gate) at different time points of differentiation. Below panel: Quantitative reverse-transcriptase 
polymerase chain reaction analysis of cardiac α-actinin (α-act) in CD166+ (white bars)and CD166− 
(gray bars) at the various times. 
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and importantly they presented insignificant levels of other germ layer or stem cell 
markers. To confirm the loss of pluripotency, in vitro proliferation assay and 
teratoma tests in CD1 nude mice have been performed; the proliferation rate 
revealed that proliferative cells were less than 4% after 48 hours;  injection of 
1,5x106 CD166+ cells did not induce teratoma in any of the animals injected after 
more than 1 year. This data clearly indicate that CD166-selected cells represent a 
safe substrate for a possible in vivo use109.  
When re-aggregated for 24 hours and plated on culture dish, CD166+, but not 
CD166-, started to beat spontaneously. This ability was maintained also in long- 
 Figure 2: Flow cytometry characterization of the CD166+ population.  
Representative dot plots showing the proportion of CD166+ cells coexpressing cardiovascular (flk-
1, Sca-1, and c-kit), mesenchymal (CD90 and CD44), and hematopoietic (CD34) markers at day 8 
of differentiation. APC indicates allophycocyanine; and FITC, fluorescein isothiocyanate. 
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Figure 3: Comparison of gene expression in early and late CD166+ cells, sinoatrial node (SAN), 
and ventricle.  
Quantitative reverse transcriptase polymerase chain reaction analysis of transcription factors 
(Tbx18, Tbx3, Isl-1, and Shox2), structural proteins, and ion channels (ssTnI, HCN4, HCN1, 
CaV1.3, CaV3.2, CaV3.1, Cx 30.2, and Cx 45) involved in SAN development and function and 
of ventricular genes (Nkx2.5, Kv 4.2, HCN2, and Cx43). *P<0.05 vs SAN; #P<0.05 vs ventricle. 
term culture (4 weeks). Therefore, subsequent evaluations regarded gene 
expression analysis in early (8 days) and late (3-4 weeks) cultures (Figure 3).  
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CD166+ cells expressed high levels of genes important in SAN development 
(TBX18, TBX3, Isl1, Shox2)76 at early days of culture, while afterwards their 
expression decreased becoming more similar to the expression levels found in the 
adult SAN. A similar situation was observed for genes involved in the SAN 
function (ssTnI, HCN4, HCN1, CaV1.3 L-type channel, connexin 30.2). Instead, 
when the expression of ventricular-specific genes (Nkx2-5, Kv4.2, HCN2, connexin 
43) was evaluated, the levels found in CD166+ at early and late days of culture 
were always significantly lower than those of the ventricle. In conclusion, these 
data on gene expression previously obtained in our laboratory showed that the 
phenotype of CD166+ is similar to that of SAN pacemaker cardiomyocytes. 
The project: current aims 
The third part of the project, which is here presented, aimed to complete the study.  
In order to support the in vitro data presenting CD166 as a good marker for early 
SAN cells, we analyzed the expression pattern of CD166 in vivo during mouse 
embryonic development. In particular, we investigated whether it is co-expressed 
with the SAN marker HCN4 in the forming heart.  
In parallel, we aimed to deepen the in vitro characterization, analyzing the 
functional aspects of CD166-selected cells, to define whether their gene expression 
similarities with the SAN correspond to an actual ability to act as biological 
pacemaker.  
First of all, to play the role of the SAN, these cells need to express functional ion 
channels required to generate action potentials. Thus, we firstly analyzed the 
functional expression of ion channels fundamental to the generation of the 
electrical impulse, such as calcium and HCN channels.  
Second, pacemaker cells need to be responsive to nervous system regulation; 
therefore, we evaluated expression of adrenergic and muscarinic receptors and 
tested cell responsiveness to their respective agonists.  
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Third, we tested the ability of these cells to connect to and pace other excitable 
cells in vitro, thus acting as a real pacemaker. 
Finally, the continuation of the project concentrated in verifying whether the 
findings in the mouse model can be applicable to a human substrate. Therefore we 
started to lay the basis for translating the protocol developed for mouse ESC to 
human induced pluripotent stem cells (iPSCs).  
  
 
15 
 
INTRODUCTION 
The heart autorhythmicity  
The mechanism of heart contraction is similar to the one of other striated muscles, 
involving actin and myosin fibers that contracts in response to electrical impulse, 
the action potential. The contractile cells of atria and ventricles receiving the 
stimulus are part of the so called working myocardium. The initiation of the action 
potential in the heart differs however from other skeletal muscles, as it is not due to 
the nervous system, but to the autorhythmic activity of a specialized tissue within 
the heart itself, called the sinoatrial node (SAN). The SAN together with the 
atrioventricular node (AVN), the His bundle and the Purkinje fibers constitutes the 
conduction tissue of the heart, which generates the electrical impulse and 
propagate it to the working myocardium (Figure 4).  
 
Figure 4: The heart conduction system.  
Cartoon of the impulse propagation in the heart. The electrical impulse is generated in the SAN 
and spreads throughout left and right atria, reaching the AVN. From the AVN, through His 
bundle branches, the impulse reaches the left and right ventricle at more delayed time. 
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Each component of the conduction tissue is able to generate spontaneous action 
potentials, but the SAN generates them at higher rate masking the activity of the 
other elements through the phenomenon known as overdrive suppression, and 
thus imposing its rhythm. For this reason, the cells of the SAN represent the 
natural pacemaker of the heart. 
The action potential generated in the cardiac cells is different from that of other 
excitable cells in shape and length. Notably, the cardiomyocytes can produce two 
types of action potentials: the working myocardium cardiomyocytes generate the 
rapid response action potentials (Figure 5A), while the SAN and the AVN cells 
generate the slow response action potentials (Figure 5B). The different profiles of 
action potential depends on different ion channels expressed on the plasma 
membrane of these cells. The slow response action potentials is characterized by 
the absence of a proper resting potential due to the activation in phase 4 of a slow 
diastolic depolarization, called also pacemaker depolarization (Figure 5B). This 
slowly leads to the threshold potential (around -40 mV) for the initiation of the 
action potential (phase 0), which is due in this case to a inward calcium current 
mediated by L-type channels, or in mouse by both sodium and calcium currents. 
Figure 5: Schematic representation of a ventricular (A) and sinoatrial (B) action potential.  
In the figure are indicated the conventional phases of the action potential and the main currents 
involved. 
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This early activation of calcium channels causes also their early inactivation; thus, 
the phase 0 is immediately followed by the ripolarization phase. The pacemaker 
depolarization is mainly attributable to a mixed sodium potassium current called 
“funny” current (If) or pacemaker current, mediated by the hyperpolarization 
activated cyclic nucleotide-gated (HCN) channels. The slow depolarization is 
favored also by the absence of the inward rectifying IK1 in these cells.    
 
Voltage-dependent calcium channels57 
 
Figure 6: L-type calcium channel structure.  
The cartoon shows the putative assemble of the various subunits of L-type calcium channels. The 
pore and ion selectivity is due to α1 subunit. (from Lancinova et al. 2005) 
Voltage-dependent calcium channels (VDCC) are activated upon membrane 
depolarization, mediate an inward calcium current and are classified into two main 
categories based on electrophysiological properties: high-voltage-activated (HVA) 
or L-type (long-lasting type) calcium channels and low-voltage-activated (LVA) or 
T-type (transient type) calcium channels. The L-type channels present high single 
channel conductance and slower kinetics of current decay, on the contrary T-type 
channels have tiny conductance and fast decay. L-type channels are responsible for 
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the depolarization phase (phase 0) of the action potential in the conduction system 
and together with the T-type channels contribute to the slow diastolic 
depolarization. The L-type calcium channels are the most studied, because T-type 
mediated currents are mostly masked by L-type currents: they can be studied only 
using pharmacological techniques.   
L-type channel structure consists in a α1-subunit, which is different for the diverse 
isoforms, that can assemble with various β-subunits and α2δ-subunits in a tissue-
specific way (Figure 6). Functionally L- and T-type calcium currents can be 
assessed thanks to the availability of more or less specific blockers. L-type calcium 
channels are blocked by nifedipine; T-type calcium channels are instead blocked 
by µM concentration of Ni2+, even though the affinity depend greatly depend on 
the α1-subunit isoform. 
 
HCN channels and If current 
The HCN channels are pore-loop cation channels structured as four subunits 
assembled to form a central pore (Figure 7).  
HCN channel mediate the If current, a time- and voltage-dependent mixed 
sodium/potassium current, which was identified for the first time in pacemaker 
cells16 and called “funny” because, differently from the other known currents, was 
activated upon membrane hyperpolarization. The biophysical properties of HCN 
channel show a higher permeability to K+ compared to Na+, which leads the If 
current to have the inversion potential at -15 mV; this is consistent with the inward 
current, constituted principally by a Na+ flux, during the slow diastolic 
depolarization phase.  
In mammals the HCN channel family comprises four isoforms (HCN1-4) coded by 
different genes, that can form homo- or hetero-tetramers10. The monomer is 
composed by six transmembrane alpha-helical segments and a N-terminal and C-
terminal regions, both located in the cytoplasm. The transmembrane segments 
include the positive charged voltage sensor (S4) and the loop between S5 and S6 
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segments responsible for the formation of the ion selective pore. The selectivity is 
guaranteed by the GYG motif, typical of highly selective potassium channels, and 
by the downstream presence of two positively charged residues and a histidine, 
providing the sodium permeability. The C-terminal domain presents a cyclic 
nucleotide-binding domain (CNBD), which permits the modulation of channel 
activity by the nervous system122 (Figure 7).  
Figure 7: HCN channel general structural organization.  
HCN channel are tetramers and each monomer is composed by six transmembrane segments. In 
red is shown S4 voltage sensor. The region comprised between S5 and S6 is the pore region, 
containing the selectivity filter motif GYG. The C-terminal domain comprises the cyclic 
nucleotide-binding domain (CNBD) organized in 3 αα-helices (A-C) and a β-roll between A- and 
B-helices. (adapted from Biel et al. 2009)  
This domain and the transmembrane core are highly conserved among the 
different HCN isoforms, while they present structural differences mainly the N-
terminus and in the length of the C- terminus. These differences produce different 
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functional properties, in the kinetics of activation and in the sensibility to cyclic 
nucleotides: HCN1 has the most rapid activation107, most positive voltage of half 
activation (V1/2), compared to HCN2 and HCN4
4, and almost no response to 
cyclic adenosine monophosphate (cAMP)122; HCN4 present instead the slowest 
activation110 and, together with HCN2, is the most sensitive to cAMP82. HCN3 is 
the less studied but it has been shown that the human channel is insensible to 
cAMP, while the mouse channel is slightly inhibited74. 
The four isoforms of HCN channels are mainly expressed in the heart and in the 
nervous system with different patterns, depending also on species and age. In the 
heart, the expression of HCN channels strongly depends on cardiac region and are 
found mostly in the conduction system rather than in the working myocardium. In 
all the studied species, HCN4 is the most expressed in the conduction system and 
in particular in the SAN, where it plays a fundamental role in generating and 
sustaining the heart beat113,120. In the SAN also HCN1 is expressed67; with HCN4 
it can form omo- or heterotetramers, resulting in channels with different 
biophysical and regulatory properties. In addition, HCN1 is expressed in the AVN 
and in the Purkinje fibers67. HCN3 is poorly express in the conduction system10. 
HCN2 is instead the isoform highly expressed in the ventricular cells and 
moderately expressed also in the atria. Nonetheless, HCN channel expression 
levels in these cells are normally low compared to those of the conduction system10.  
Regulation of cardiac activity by the nervous system 
Although the cardiac electrical activity is not initiated by the nervous system, it can 
influence the beating rate, modulating the cytoplasmic level of cAMP. This 
regulation is performed by the neurotransmitters noradrenaline and acetylcholine 
released by the sympathetic and the parasympathetic branches of the autonomic 
systems, respectively. Once secreted, noradrenaline bind to β-adrenergic and 
acetylcholine to muscarinic receptors on the plasma membrane (Figure 8). These 
receptors are coupled to trimeric G proteins. β-adrenergic and muscarinic receptor 
activations produce opposite effects though, because they are associated with 
different types of G protein, the stimulating Gαs and the inhibiting Gαi, respectively. 
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Indeed, adrenaline stimulation causes an increase of intracellular cAMP, while 
acetylcholine induces a decrease. Higher levels of intracellular cAMP increase the 
opening probability of HCN channels that causes a shift in the activation curve 
towards more positive potentials. This implies that at the same membrane potential 
the amplitude of If current is larger, leading to a steeper slow diastolic 
depolarization phase that  results in higher firing rate of action potentials26. 
On the contrary, lower levels of intracellular cAMP due to muscarinic stimulation 
decrease the opening probability of HCN channels, which slows down the diastolic 
depolarization phase and thus decreases the beating rate27.  
 
The embryionic development of the heart 
The heart is the first organ that becomes functional in the embryo. Its formation is 
extremely complex and this is consistent with the high incidence of congenital 
heart abnormalities in the population97.  
During gastrulation, in the developing embryo three germ layers are formed: 
ventrally the endoderm, dorsally the ectoderm and the mesoderm in between. The 
Figure 8: Schematic representation of the activation of β-adrenergic and muscarinic receptors.  
Epinephrine bind to the β-adrenergic receptor inducing the activation of the stimulatory G protein 
complex which in turn acts on adenylyl cyclace, causing an increase in cAMP synthesis. 
Acetylcholine binds to the muscarinic receptor inducing the activation of the inhibitory G protein 
complex, which in turn inhibits adenylyl cyclace, causing a dccrease in cAMP synthesis. 
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mesoderm is then further subdivided into somatic and splanchnic layers by the 
formation of the intra-embryonic coelum.  
The heart originates from few cells of the splanchnic mesoderm that compose the 
so called lateral mesoderm, that is the anterior part of the primitive streak. These 
precursors are committed to the cardiac phenotype during and immediately after 
gastrulation, and are induced to migrate giving rise two bilateral heart-forming 
fields. The transcription of particular genes guides the specification of the 
splanchnic mesoderm into cardiogenic mesoderm. This fate is imposed by stimuli 
arising from neighbouring cells: a positive regulation from the endoderm, 
including Hedgehog, FGF, transforming growth factor and BMP signalling; and a 
suppression from the neural plate and the somatic mesoderm, mostly due to Wnt 
signalling97 (Figure 9A). For cardiac specification in vertebrates the T-box 
transcription factor Eomes is required6, which activates Mesp1 that down-regulates 
pluripotency genes and up-regulates cardiac transcription factors such as Gata4, 
Nkx2-5 and Mef2c.  
Afterwards, the cells of the heart-forming field migrate to the midline originating 
the cardiac crescent. During the subsequent folding of the embryo, the cardiac 
crescent becomes a bowl-shaped heart. The cells forming this primitive heart are 
the first precursors to differentiate and are therefore named the “first heart field” 
(FHF). Notably, most of the cardiac mesoderm cells remain in an undifferentiated 
state for a longer period of time, maintaining high proliferation rate, and are then 
progressively added to the primitive heart tube to allow its elongation. Since these 
precursors present a delayed differentiation, they are called the “second heart field” 
(SHF)97. In a subsequent phase, the bowl-shaped heart detaches form the dorsal 
coelum wall and form a close heart tube. In this phase the cells are already 
committed to originate different heart region: the sinus venosus originating the 
SAN, the atria, the ventricles, the cardiac bulb and the outflow tract. Lineage 
tracing experiments revealed that the FHF is responsible for the development of 
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 the primitive ventricle originating the left ventricle, while the other regions of the 
heart require the contribution of SHF cells78.  
 
Figure 9: Cell fates during heart embryonic development.  
(A) Schematic representation of the stimulatory and inhibitory signals arising from the endoderm 
and the notochord (ectoderm) to induce the cardiogenic mesoderm. (from Rana et al. 2013) 
(B) Schematic representation showing the fate map of the cardiac mesoderm. The FHF (grey) 
originates the left ventricle, the SHF originate the atria, while sinus venosus progenitors belong to 
a population placed in the caudal-lateral part of the cardiogenic mesoderm. A, atrium; AIP, 
anterior intestinal portal; CCV, common cardinal vein; EV, embryonic ventricle; HT, heart tube; 
OFT, outflow tract;VEN, ventral; DOR, dorsal; CRA, cranial; CAU, caudal: L, left; R, right. (from 
Mommersteeg et al 2010) 
 
The addition of SHF cells is parallel to an asymmetric growing of the cardiac tube 
determining the left-right differences necessary to the chamber formation. The 
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outer curvature of the heart tube begins to express a specific set of genes that cause 
a localized differentiation and proliferation of cells, eventually leading to the 
expansion of the atria and the ventricles. This process reminds the inflation of a 
balloon and thus it is called the ballooning model of chamber formation97. First, 
the right ventricle is formed, thanks to the so called primary ring79 located at the 
position where the ventricular septum will develop. Further folding of the heart 
completes the chamber septation.  
In the forming heart, the cells of the prospective SAN, AVN and His bundle 
represent a small subset which retains the embryonic phenotype. Indeed, they 
share many characteristics with the primitive embryonic myocardium such as a 
high glycogen content, a less developed sarcomeric organization and fewer 
mitochondria. In particular, the SAN cells originate from the caudal-lateral region 
of the splanchnic mesoderm, which is distinct from FHF and SHF75 (Figure 9B). By 
day 8.5 of mouse embryonic development, these precursors present a specific gene 
signature: they express T-box 18 (TBX18), Islet 1 (ISL1) and SHOX2, but do not 
express Nkx2-5, which is instead crucial for cardiac looping and thus chamber 
formation76. Shox2 represses Nkx2-5 expression in a specific region where the 
sinus venosus can develop, allowing the expression of the SAN-specific genes 
TBX3 and HCN4; the former represses the expression of working myocardium 
genes, while the latter codes for the pacemaker channel mediating If.  
Pathological alterations of the heart rhythm71,123 
Normally, the beating rate can increase or decrease depending on the body 
activity or condition. The heart rate depends also on the developmental stage, 
since in the newborn and in the fetus it results higher compared to adults. This 
variability in heart rate is mainly due to the autonomous nervous system 
stimulation or to hormonal response.  
Under some pathological conditions, for example if the SAN firing rate decreases 
under a certain threshold, other regions of the conduction system can prevail on 
the basis of the overdrive suppression, generating ectopical foci or latent 
pacemakers. In particular, in case of a block of the SAN activity, the AVN 
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supplants its role. However its rate is significantly slower and although it can 
prevent heart block, it cannot sustain increased oxygen demand and this may 
cause serious problems such as ischemia. On the other hand, the emergence of 
ectopical foci can lead to premature atrial or ventricular contraction that may cause 
paroxysmal ventricular tachycardia, atrial or ventricular fibrillation, pathologies 
that increase the risk of heart failure.  
The heart rhythm disorders can occur also for dysfunctions in the conduction of 
the signal, despite the proper generation by the SAN. This is often due to 
inflammation, fibrosis or ischemia or to the treatment with some drugs. The 
pathological condition that can arise in this case is called heart block or atrio-
ventricular block, which can present diverse levels of severity, the worst being the 
complete block of the conduction from atria to ventricles.   
The pathologies arising from heart rhythm disorders are initially contrasted with 
pharmacological treatment. However, when these treatments are not sufficient, the 
implantation of an electronic pacemaker is needed. The electronic pacemaker is a 
device composed by an impulse generator, a connector and two electrodes that 
are placed on the right atrium and right ventricle (Figure 10). This device is 
implanted for example in the case of pathologies resulting in lack of blood flow to 
the brain, such as Stokes-Adams syndrome, or for complex cardiac dysfunctions, 
such as the Sick Sinus Syndrome, or in cases of severe atrio-ventricular block.  
In the last years, an increase in the electronic pacemaker implantation has been 
reported and notably this is mainly due to isolated sinus node dysfunctions11. This 
increase can be attributed to the population ageing and thus it is probable that this 
phenomenon will further grow in the next years.  
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Figure 10: The electronic pacemaker. 
The drawing shows a general overview of the electronic pacemaker device, composed by a pulse 
generator connected with two electrodes to the right atrium and right ventricle.  
 
The artificial pacemaker: from electronic to biological 
Although life-saving, the electronic pacemakers present several limitations. Beside 
showing an inhibiting interactions with other common electronic devices of daily 
life, electronic pacemakers need above all a periodic maintenance. The battery 
must be usually replaced after 7-10 years46 and this occurs in the 25% of all 
implantation procedures77. The replacement is an invasive surgery with costs and 
some risks of complications such as infections. To overcome this problem, efforts 
in developing alternatives to the currently used lithium batteries are ongoing. 
Many attempts focused on building self-powered devices based on energy 
harvesting systems39,46. However, the amount of the harvest energy resulted not 
enough to power a pacemaker. Recently, a study from Hwang and colleagues46 
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used a material with high piezoelectric coefficient to electrically stimulate heart 
beating in a living rat, increasing output current efficiency. In another recent study, 
Haeberlin and colleagues39 developed a sunlight-powered pacemaker with 
subcutaneous implantation, that provide enough energy and has a predicted 
lifetime of 20-30 years. Even though the technique is interesting and very new, 
important limitations to this study must be considered, such as the test limited to 
only one pig, the issues concerning skin color for subcutaneous light penetration 
and the need of a large capacitor for energy storage to pace during darkness.   
Despite the improvements of newly available technologies, the electronic 
pacemaker remains a device which cannot perfectly integrate within the body of 
the patient and importantly it is not sensible to nervous system and hormonal 
regulation. This leads to a reduced response in case of physical or emotional stress 
that may results in inconveniences or even in dangerous conditions.  
For this reason, the scientific community is focusing on the development of a 
“biological pacemaker”, that is a cellular substrate able to generate and transmit 
the electrical impulse and to integrate in the cardiac tissue, thus responding to the 
nervous and hormonal regulation. The idea is to use cells that share the 
pacemaker characteristics of SAN cardiomyocytes. The strategies used to reach 
this goal until now are of two types: the “gene therapy”, aiming to genetically 
modify cardiac cells in order to generate or to increase the spontaneous 
autorhythmic activity; and the “cell therapy”, aiming instead to build a new tissue 
that can be implanted and function as a pacemaker.  
The initial examples of the first strategy come from the works of Edelberg et al.31 
and Miake et al.72 from the early 2000s. The first group overexpressed the β-
adrenergic receptor by injection of a plasmid in a mouse right atrium. This 
produced an increase in beating rate, however it was transient and involved a over-
activation of adrenergic system that at a certain point cause desensitization of the 
receptors31. The latter group attempted instead to convert ventricular myocytes 
into pacemaker cells inhibiting the IK1 current by means of viral expression of a 
dominant mutant72. This approach presented the important limitation of generating 
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ectopical foci in the ventricle leading to arrhythmias. In addition, no regulation of 
the nervous system was observable.  
Subsequent studies focused on the expression of HCN channels in ventricular 
myocytes.  HCN channels present the advantage to be active only during the slow 
diastolic depolarization phase and to be modulated by the nervous system. Qu et 
al.96 succeeded in expressing the HCN2 gene in vivo in the left atrium of a dog, 
obtaining an autorhythmic area able to be modulated by nervous system. Because 
gene transfer was mediate by an adenovirus, the effect of the infection was 
transient though, and this method presents the risks of infection or neoplasia 
connected to the use of a viral vector.  
The most recent study based on gene therapy was performed by the group of H.C. 
Cho, who delivered the TBX18 first into rodent ventricular cardiomyocytes53 and 
later in pig models of heart block treated with electronic pacemakers44. They 
demonstrated that the expression of TBX18 can convert quiescent cardiomyocytes 
into pacemaker cells both in vitro and in vivo. In addition, after 14-days follow-up 
the TBX18-injected pigs showed enhanced response to nervous system and 
chronotropic support to physical activity compared to animals implanted with only 
the electronic pacemaker. In these studies an adenoviral vector was used, which 
allows shorter term virus expression, however a decline of heart rate was observed 
after 11 days in both TBX18-transduced and GFP-transduced control animals, 
suggesting that the adenoviral itself may have an effect. Notably, some adenoviral 
vector may cause inflammation that can induce impulse initiation104.  
The same research group who infected HCN2 in dog atrium, attempted also to use 
the strategy of cell therapy, by expressing HCN2 in adult mesenchymal stem cells 
and using these cells to induce action potentials in endogenous myocytes, as a 
passive pacemaker. Nevertheless, this approach used a viral vector and adult 
mesenchymal stem cells which are little controllable and can differentiate in other 
cell types93.  
More recently, Cho et al.21 overcome the problem of using not fully differentiate 
cells by overexpressing HCN1 into fibroblasts and by fusing them with the 
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endogenous cardiomyocytes. It remains to be elucidated whether this system can 
have a long-term effectiveness, especially in vivo.  
A promising strategy to obtain pacemaker cells is the in vitro differentiation of 
embryonic stem cells (ESCs) or of induced pluripotent stem cells (iPSCs) (Figure 
11).  
 
Figure 11: Scheme of the cell therapy approach for generating a biological pacemaker using 
pluripotent stem cells. 
The figure summarize the principal phases of the stem cell-based idea. Human iPSCs obtained 
reprogramming patient cells are differentiated in culture. During differentiation, SAN precursors 
are selected and used to generate a de novo cell substrate that can be implanted back in the 
patient to restore the proper heart rhythm. 
 
These cells can be induced to differentiate in vitro into cardiac cells, which 
spontaneously beat in culture. 
The actual capability of ESC-derived cardiomyocytes to pace other cells was 
demonstrated by  Kehat et al. and subsequently by Xue et al.. The first group 
showed that cardiomyocytes obtained by hESC spontaneous in vitro differentiation 
expressed gap junction, integrated in vitro with rat cardiomyocytes and were able 
to sustain heart rhythm in vivo of 50% of atrioventricular blocked pigs54. Also Xue 
et al. demonstrated that hESC-derived cardiomyocytes can functionally integrate 
with co-cultured quiescent cardiomyocytes and in vivo in guinea pig left 
ventricle129. 
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Despite the powerful proof-of-concept of these works, the method is limited by the 
fact that pacemaker cells represent only a small fraction of the obtained cell types 
interspersed among the others7. The main challenge with this approach is then to 
isolate a homogenenous cell population that shows a pacemaker phenotype and 
that has lost the characteristics of pluripotency leading to teratoma formation.  
An initial attempt of pacemaker cell selection upon ESC differentiation was 
performed by Morikawa et al.81 using HCN4 as selection marker. They used an 
engineered cell line with HCN4-driven expression of the green fluorescent protein 
(GFP). Unfortunately, in the GFP-positive cell population, the 65% did not present 
autorhythmic activity and some of them expressed neuronal markers.  
Pluripotent stem cells: an in vitro model 
Stem cells are undifferentiated cells able to differentiate in many cell types. They 
are able to indefinitely self-renew maintaining their undifferentiated state and at the 
same time to differentiate into somatic cells, through asymmetrical division. The 
stem cells are divided into different types, based on their origin and their 
differentiation potential. The zygote cells until the 4/8-cell stage are the only 
totipotent cells, that are the cells able to give rise to all embryonic and 
extraembryonic tissues. ESCs are cells derived from the inner cell mass (ICM) of 
the blastocyst and are pluripotent, as they can give rise to all the cell types of the 
body but not to the extra-embryonic tissues. The adult stem cells present instead a 
reduced differentiation potential, as they are multipotent, thus able to differentiate 
only into the cell types of some precise tissues or organs (Figure 12). These stem 
cells are present the adult organism with the main function of regenerating the 
damaged tissues. The iPSC are cells artificially reprogrammed to the pluripotent 
state from cells already differentiated. They present characteristics similar to ESCs. 
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Figure 12: Scheme of cell differentiation potentials during development. 
The bar on the left indicate the decreasing differentiation potential. The totipotent zygote has the 
highest differentiation potential, the ES cells are pluripotent and can differentiate in all the three 
germ layers: ectoderm, endoderm and mesoderm. The precursors cells of these layers comprise 
also adult stem cells and are multupotent. The finally differentiated somatic cells can originate 
only a precise cell type, because they are unipotent. (from Berdasco and Esteller 2011) 
ESCs 
ESCs can be cultured in vitro at the undifferentiated state, present a normal 
karyotype and grown indefinitely without undergoing senescence128. Mouse ESCs 
are the most used in research laboratories. They can grow as couple-shaped 
colonies on feeder-layer of mouse embryonic fibroblast that supplies the stimuli for  
proliferation and survival maintaining ESCs undifferentiated. They can also grow 
in suspension in a feeder-free condition, provided that the leukemia inhibitor factor 
(LIF) is added to the culture medium68. This factor induces the inhibition of MAP 
kinase (MAPK) pathway and the expression of some transcription factors, such as 
Oct4, Nanog and Sox2 which maintain the pluripotent state19. The properly 
 
32 
 
cultured ESCs can be recognize by the expression of some surface antigens, such 
as SSEA-1 (stage-specific embryonic antigen 1) for mouse cells, and by the high 
activity of alkaline phosphatase or telomerase. Notably, in vivo they produce 
teratoma. 
An important application of mouse ESCs is the in vitro differentiation. Diverse cell 
types can be obtained, such as cardiac, neuronal, skeletal muscle, blood, adipose 
tissue cells128. The ESC differentiation tool is particularly relevant in order to 
obtain cell types that cannot be kept in culture after isolation from the adult animal 
models, such as cardiomyocytes or neurons. Another important advantage of ESC 
differentiation is the possibility to study in vitro the effects of mutations of 
particular genes and test a proper treatment at different stages of development.  
The differentiation can be induced toward a specific cell type based on the 
composition and the factors present in the culture medium. It is firstly operated by 
removing the undifferentiated state keepers (LIF or feeder layer cells) and by the 
formation of cell aggregates called embryoid bodies (EBs) that recapitulate the 
embryonic development. The EBs can be obtained through the “hanging drop” 
method by which a defined number of cells is clumped within small drops hanging 
from the bottom of an inverted dish. The EBs are subsequently cultured in 
suspension for a determined period (4-7 days) while they receive gradually 
decreasing amount of stimulant factors from the outer to the inner part. This 
diversification address the cells to the different embryonic germ layer fates. The 
EBs are then plated and let to adhere in order to obtain the final differentiation in 
a specific cell type. The ESC-derived cells show the properties of the 
corresponding in vivo cell type. In fact, ESC-derived cardiomyocytes express the 
ion channels that allow them to produce spontaneous action potentials and to 
contract in culture. They are a mixture of atrial-like, ventricular-like and 
pacemaker-like cells, as defined by electrophysiological characterizations7,42. In 
particular ESCs are the only cell type able to originate pacemaker cells.   
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iPSCs 
The iPSCs can be obtained using three different technology of somatic cell nuclei 
reprogramming: the nuclear transfer, the fusion of somatic cells with stem cells and 
the reprogramming induced by specific transcription factors. These methods are 
able to force a completely differentiated cell again to a pluripotent state changing 
its genetic expression profile130. 
 
Figure 13: Schematic representation of reprogramming of somatic cells into iPSCs. 
The Yamanaka method consists in the infection of somatic cells with Oct4, Sox2, Klf4 and c-Myc. 
The expression of these genes induces the reprogramming and the appearance of iPSC colonies.  
In 2006 Shinya Yamanaka hypothesized the existence of trascriptional factors in 
ESC that could reprogram the genome of a somatic cell again into a pluripotent 
stem cell. Among 24 different selected factors, he demonstrated that only 4 factor 
are sufficient and necessary to reprogram a somatic cell into a pluripotent stem 
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cell: Oct4, Sox2, Klf4 and c‐Myc118 (Figure 13). Human iPSCs were thus generated, 
reprogramming human skin fibroblasts using Yamanaka factors (Oct4, Sox2, Klf4 
and c-Myc)117 and also using a similar cocktail factors (Oct4, Sox2, Nanog and 
Lin28)134. The cell lines obtained from these protocols have the same morphologic 
characteristic, the same expression markers and the same plasticity of mESC in 
vitro, so they are defined induced pluripotent stem cells.  
To introduce the transcriptional factor within the somatic cells the Yamanaka 
protocol involves the use of retroviral or lentiviral vectors bringing the information 
of the four transcriptional factors. This strategy induces the permanent integration 
in the genome of the exogenous genes; their initial expression necessary for a 
correct reprogramming is down-regulated autonomously by the iPSC, while the 
endogenous genes are activated.  
Different reprogramming procedures are being investigated involving miRNA5, 
episomal vector133, recombinant protein55 or Sendai virus35,87,111. 
Also iPSCs, as ESCs, can differentiate in vitro into the cell types of the three germ 
layers23,83. Concerning human cells, iPSCs are pluripotent cells lacking the ethical 
problems associated with human ESCs, because are obtained reprogramming cells 
coming from biopsies, usually of the skin. hiPSCs present also the advantage of 
having the same genome of the patient, and so do the cells differentiating from 
hiPSCs. The generation of patient-specific cells is important for clinical 
applications; for example in the regenerative medicine this can avoid the 
phenomena of rejection.  
Activated Leucocyte Cell-Adhesion Molecule (ALCAM) or CD166 
ALCAM, also called CD166 (cluster of differentiation 166) or in some cases CD6 
ligand (CD6L), is a transmembrane protein belonging to the superfamily of 
immunoglobulins, involved in homotypic and heterotypic (with the T-lymphocyte 
stimulatory molecule CD6) adhesions13. The main function of CD166 is to mediate 
cell-to-cell contacts in epithelia, mesenchymal, neuronal and connective tissues. 
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Indeed, it plays a role in many different processes, such as cell migration,  
hematopoiesis, immune response41, orientation and extension of axons20, and it is 
also deregulated in many forms of tumor, leading to migration and metastasis124.  
In addition, it has been shown to be expressed during embryonic development. It 
results transiently expressed in the human blastocysts, where it appears to be 
involved in the early interaction of the embryo with the maternal endometrium34. 
CD166 expression is instead silenced in several adult tissues, being confined in the 
above cited tissues.  
An interesting study showed that CD166 is specifically expressed at day 7.5 of 
mouse embryonic development in the cardiac crescent, while at day 8.5 high levels 
are found in the cardiac tube and in the sinus venosus. Notably, at day 12.5 
CD166 expression is not associated to cardiac cells anymore, but its expression 
broadens to other organs43. Subsequent studies demonstrated that the CD166 is 
expressed in the mouse yolk sac, both in endothelial and cardiac precursors. The 
latter are however recognizable by the lack of Flk-1 expression, while the Flk-
1/CD166 positive cells give rise only to endothelial cells84. Other developmental 
studies in Xenopus Laevis, showed that CD166 is involved in the morphogenesis 
and maintenance of the FHF giving rise to the cardiac tube38.  
Recently, Rust and collaborators obtained a population enriched in 
cardiomyocytes by selecting CD166-positive cells at day 12 of human ESC 
differentiation. This population expressed the L-type calcium, sodium and 
pacemaker ion channels and contractile proteins such as α-actinin, tropomyosin, 
alpha-myosin heavy chain (MHC) and atrial myosin light chain 2 (Mlc2a), typical 
markers of cardiomyocytes. These cells are shown to beat in culture for 3 weeks if 
they were seeded at high densities promoting cell aggregation in suspension105.  
Interestingly, CD166 is also expressed in the human fetal heart, specifically in 
cardiomyocytes and not in smooth muscle cells neither in endothelial cells61. In 
agreement with this, also iPSC-derived cardiomyocytes and not smooth muscle or 
endothelial cells were shown to be positive to CD166 signal in 
immunofluorescence analysis61. The same study used CD166 ad a selection 
marker for cardiomyocytes from multipotent cardiovascular progenitors at day 20 
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of iPSC differentiation, although expression of CD166 was present also during all 
the differentiation period.  
These evidences suggest that CD166 could be a suitable marker to select 
cardiomyocytes upon pluripotent stem cell differentiation in a specific time-window.  
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MATHERIALS AND METHODS 
Embrionic Stem Cell culture and differentiation 
Mouse ESCs (D3 line, ATCC) were grown in suspension in ES-medium containing 
ES-DMEM (ATCC), 15% Knock-Out Serum Replacement (Life Technologies), 0.1 
mM Non Essential Amino Acids (Life Technologies), 0.1 mmM β-mercaptoethanol 
(Sigma-Aldrich), 2 mM L-glutamine (Life Technologies), 103 U/ml Leukemia 
Inhibitory Factor (LIF, Chemicon), 1X  PenStrep  (100U/ml  Penicillina and 
0,1mg/ml Streptomicina, Sigma-Aldrich) and were differentiated with the “hanging 
drop” method. ESCs were divided with Tryple Express (Life Technologies) 
obtaining an homogeneous suspension, counted and resuspended at specific 
density (2,5x104 cells/mL) in a differentiating medium containing DMEM (Life 
Technologies), 4mM L-Glutammine (Sigma-Aldrich), 0,1mM β-Mercaptoethanol 
(Sigma-Aldrich),  0,1mM  Non  Essential  Aminoacids  (NEA,  Life Technologies),  
20%  Fetal  Bovine  Serum  (FBS, Life Technologies),  1mM  Na-Piruvate  (Sigma-
Aldrich),  1X  PenStrep  (Sigma-Aldrich). ESCs were then cultured as hanging 
drops containing ~ 500 cells/20 µl for 2 days at 37°C with 5% of CO2 and then they 
were grown in bacterial dishes for 5 days. 7 day-old Embryoid Bodies (EBs) were 
plated on tissue culture dishes coated with gelatin 0.1% (Type B, Sigma) in 
differentiating medium containing: DMEM (Life Technologies), 4mM L-glutamine 
(Life Technologies), 0.1 mM NEA (Life Technologies), 0.1 mM β- mercaptoethanol 
(Sigma), 20% FBS (Life Technologies), 1X PenStrep and let to grow for one day 
before enzymatic dissociation and sorting. 
The pHCN4-EGFP clone of mouse ESCs was obtained cloning 841 bp sequence 
located 2.30 Kb upstream of the 5’ ATG of the mouse HCN4 gene, and 
corresponding to its promoter (pHCN4), and inserting it into the expression vector 
pEGFP-N1 (Clontech) after removal of the constitutive CMV promoter. The 
resulting pHCN4-EGFP plasmid carries the enhanced green fluorescent protein 
(EGFP) under the transcriptional control of the pHCN4. 2x106 mouse ES D3 cells 
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were nucleofected (Mouse ES nucleofector kit VPH-1001, A24 program, Amaxa) 
with 10 μg of pHCN4-EGFP plasmid and plated in 100 mm dishes in ES-medium. 
To induce plasmid integration, cells were kept under stringent selection (600 μg/ml 
of geneticin) for at least two weeks, changing the medium every two days. After 
this period, the geneticin concentration was lowered to 300 μg/ml. 
Generation of human iPS from somatic cells 
Dermal biopsies from healthy individuals were maintained in DMEM at 4°C. The 
tissue was cut in small pieces and incubated in DMEM plus 10% FBS, 2 mM L-
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C with 5% CO2. 
Culture medium was changed every 3-5 days until visible outgrowths of cells are 
obtained (usually 1 to 3 weeks). Adherent cells coming out of the tissue were 
enzymatically dissociated and re-plated to allow for fibroblasts expansion. 
Subsequently, cells were reprogrammed using CytoTune®-iPS 2.0 Sendai 
Reprogramming Kit (Life Technologies). Colonies that microscopically present a 
human iPS-like morphology were manually picked with a micropipette, initially 
expanded on a feeder layer of murine embryonic fibroblast (MEF), and adapted 
later to grow on feeder-free, Matrigel™-coated plates in iPSC complete medium, 
composed by: Knockout DMEM, 20% Knockout serum, 1% B27 supplement, 1% 
N2 supplement, 2mM GlutaMAX (Life Technologies), 1mM 2-mercaptoethanol, 
0.1 mM NEA solution (Sigma Aldrich), 1X PensStrep and 20 ng/ml bFGF (Life 
Technologies). Selected colonies were then analyzed for the expression of the 
pluripotency transcription factors (OCT4, SOX2, NANOG) by quantitative real-
time PCR. 
Differentiation of human iPS 
For “spontaneous differentiation protocol” of iPSCs, colonies growing on the 
feeder layer were adapted to grow on Matrigel™ using mTeSR™1 (Stem Cell 
Technologies) as maintenance medium to avoid feeder cell contamination during 
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the differentiation protocol. Cardiac differentiation were induced by aggregation of 
human iPSCs (hiPSCs) into EBs by detaching and re-plating them on ultra-low 
attachment plates in EBs medium, composed by: DMEM/F12, 20% FBS, 0.1 mM 
NEA solution, 0.1 mM GlutaMAX, 50 μM 2-mercaptoethanol, 1X PenStrep (Life 
Technologies). On day 6, EBs were transferred to 0.1% gelatine-coated plates and 
monitored for the next 6-7 days for the appearance of spontaneously beating areas. 
At the appearance of spontaneously contracting areas, serum (FBS) concentration 
in EBs medium will be lowered to 2%. The beating clumps will be manually 
dissected with a microscalpel and transferred to gelatin-coated plates. They were 
kept in culture for several days before detaching them for the different analysis.  
For “induced differentiation protocol”, the commercial kit from Life Technology 
was used, consisting in a mono-layer differentiation using definite factor-containing 
culture media (medium A for days 0-2, medium B for days 2-4, medium C for days 
4-14 of differentiation) that actively induce mesoderm and then cardiac 
differentiation activating intracellularly specific signalling pathways, leading to a 
general increase in the yield of cardiomyocytes.   
Flow cytometry and cell sorting 
For flow cytometry analysis and sorting EBs from mouse ESCs or human iPSCs 
were collected and washed twice in PBS, subsequently treated with Tryple Express 
(Life Technologies) for 10 min at 37°C under gentle agitation, and then 
mechanically dissociated. The cell suspension was centrifuged at 310 x g for 15 
min and resuspended in PBS plus 1 mM CaCl2, 10% FBS and 5 mM EDTA. Cells 
were incubated with the fluorophore-conjugated antibody PE Rat anti-mouse 
CD166 (eBioscience) for 30 min on ice, under gentle agitation in the dark. After 
incubation, cells were washed twice in PBS and resuspended in PBS with the 
addition of 1 mM CaCl2, 5 mM EDTA, subsequently filtered through a 70 m 
sterile mesh and analyzed by a FACSAriaTM flow cytometer and sorter (BD 
Biosciences). The appropriate isotype control and unstained cells were used to set 
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the FACS conditions. For following analyses, ES-derived cells were re-aggregated 
by gravity for 24h in low-adhesion culture dishes in differentiating medium and 
then plated at either low density for electrophysiological analysis or at high density 
to allow the formation of a compact layer for immunoistochemistry analysis inside 
silicon inserts (Giemme), which were removed after about 3 hours.  
Mouse embryo tissue sections staining  
Mouse embryos at developmental stage E10.5 and E12.5 were isolated from CD1 
female mice, then collected in cold PBS and after that fixed in 4% 
paraformaldehyde for 1 or 2 hours respectively. The embryos were washed twice 
in PBS, dehydrating them by washing in PBS containing increasing concentration 
of sucrose (10, 20 and 30%), included in O.C.T compound and frozen in liquid 
nitrogen-cooled isopentane. Serial 8-µm-thick sections were cut with a Leica cryostat 
(Leica Microsystems GmbH, Wetzlar, Germany) and the cryosections were 
incubated in PBS with 1% BSA and 0.1%TritonX-100 for 1 hour at room 
temperature subsequently blocked with 10% donkey serum in PBS for 30 minutes 
at RT. The samples were incubated with the primary antibody (anti-CD166; 1:50 
or anti-HCN4 1:50) overnight at 4°C followed by secondary staining with 
secondary antibody 1:250 Alexa488 donkey anti-goat for 1 hour at RT. Slides were 
then washed three times in PBS, incubated with Hoescht (1mg/ml for 5min at RT), 
washed, mounted using Fluorescence Mounting Medium (Dako) and analyzed at 
fluorescence microscopes (Leica). 
Immunofluorescence and Video-Confocal Analysis 
Samples were fixed on ice in paraformaldehyde (4%) for 30 minutes, rinsed for 20 
min with PBS containing 0.1 mM glycine, then permeabilized with 1.5% Triton X-
100 in PBS for 30 min and subsequently incubated in a solution containing 0.3% 
Triton X-100, 1% (w/v) Bovine Serum Albumin (BSA), 10%  Normal Donkey 
Serum in PBS for 1 hour. Samples were incubated overnight at 4°C with primary 
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antibodies in PBS, 0.3% Triton X-100, 1% Bovine Serum Albumin (BSA), and 2% 
Serum. The antibodies used were: mouse anti-caveolin-3 (1:500, BD Biosciences); 
mouse anti-α-actinin (1:700, Sigma); rabbit anti-HCN1, -HCN2 and -HCN4 (1:100, 
Alomone Labs); rabbit anti-β1 (1:50, Santa Cruz) and anti-β2 adrenergic receptors 
(1:50, Santa Cruz); mouse anti-muscarinic M2 receptors (1:200, Santa Cruz). The 
day after samples were washed in PBS and incubated for 1 hour with PBS, 0.3% 
Triton X-100, 1% BSA, 2% Normal Donkey Serum and the appropriate 
fluorophore-conjugated secondary antibodies (donkey anti rabbit Alexa594, 
donkey anti-mouse Alexa488, goat anti-rabbit Alexa 405 1:500, 1:1000 Molecular 
Probes). After a final washout in PBS, coverslips were mounted with Vectashield 
mounting medium with DAPI (Vector) and confocal images were then acquired 
using a video confocal microscopy ViCo (Nikon). 
Neonatal cardiomyocytes isolation and (co-)cultures 
Neonatal rat cardiomyocytes were isolated from rat pups of 2 days. The hearts 
were isolated and then maintained into a PBS solution. Atrium were eliminated 
and the ventricles were kept in a dish with PBS; then the ventricles were cut into 
pieces and transferred into a 15 mL Falcon, discarding the supernatant. 0,3 mL of 
enzymatic solution (in mM: 116,4 Nacl, 5,4 KCl, 1 NaH2PO4 H2O, 0,8 MgSO4 
H2O, 5.5 Glucose, 20  Hepes, 0,4 mg/ml Pancreatine and 136 U/ml of Collagenase 
Type 4) were added for each heart and stirred at 37°C for 20 minutes. At the end 
of the digestion, the supernatant was transferred in a 15 mL tube adding 1 mL of 
filtrate FBS to inactivate the enzymes. After a centrifuge of 5 minutes at 300 x g the 
supernatant were discarded and the pellet were gently resuspended into a tube 
with 1 mL of FBS, keeping the tube on ice. With the remaining pieces the 
digestion with enzymes were repeated for almost 4 times. At the end of the 
digestions the tube was centrifuged at 300 x g and pellet resuspended slowly in 1 
mL of medium and plated into a 100 mm dish, waiting 40 minutes to allow the 
adhesion of fibroblast. At the end, the supernatant was plated into a different dish 
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and maintained in culture with a medium containing DMEM/M199 (Life 
Technologies™), adding 10% of  HS (Horse Serum) (Life Technologies™), 5% of 
FBS (Fetal Bovine Serum) (Life Technologies™), 1% of L-Glutamine (Sigma-
Aldrich®) and 1% of Pen/Strep (penicillin 100U/mL, streptomycin 0,1mg/mL) 
(Sigma-Aldrich®). Cardiomyocytes were maintained in incubator at 37°C with 5% 
of CO2. For co-culture experiments, either 2.5x10
5 re-aggregated CD166+ or 
CD166- were plated in square silicon supports (0.03 cm2, Ibidi). After 4 hours the 
support was removed and the culture medium was changed the next day. After 3-4 
days, 8x105 rat neonatal ventricular myocytes were plated, in a delimited area 
using a cloning cylinder. The inserts were removed after about 3 hours. Co-
cultures were kept in differentiating medium for at least 3-4 days before 
electrophysiological analysis. 
Electrophysiology 
For electrophysiology, cells were placed onto the stage of an inverted microscope 
and were superfused with a physiological solution called Tyrode containing (mM): 
140 NaCl, 5.4 KCl, 1.8 CaCl2, 1 MgCl2, 5.5 D-glucose, 5 Hepes-NaOH; pH 7.4. 
Patch-clamp pipettes had resistances of 5-8 M when filled with the intracellular 
solution containing (mM): 130 K-aspartate, 10 NaCl, 5 EGTA-KOH, 2 CaCl2, 2 
MgCl2, 2 ATP (Na-salt), 5 phosphocreatine, 0.1 GTP (Na-salt), 10 Hepes-KOH; 
pH 7.2. Spontaneous action potentials were recorded by the patch-clamp 
technique in current clamp mode using the whole-cell configuration. For each 
experiment, temperature was kept at 36±1°C. Isoproterenol (Iso), acetylcholine 
(ACh), nifedipine or Ni2+ (Sigma) were added to the Tyrode solutions at the 
proper concentration from concentrated stock solutions. For voltage-clamp 
recordings only single cells were used in order to record ion currents and were 
also added 1 mM BaCl2 and 2 mM MnCl2 to the Tyrode solution to improve 
dissection of If current. To record If, from a holding potential of -35 mV a 
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hyperpolarizing test steps long enough to reach steady-state current activation to 
the range -45/ -125 mV were applied followed by a steps at -125 mV, which ensures 
the opening of all channels. The activation curves were obtained from normalized 
tail currents measured at -125 mV and fitted to the Boltzmann equation:  
y = 1/{ 1 + exp [( V-V½) /s]} 
where V is voltage, y fractional activation, V
1/2 
the half-activation voltage, and s the 
inverse-slope factor.  
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RESULTS 
CD166 is co-expressed with HCN4 during embryonic development of the 
heart 
The data previously obtained in this study presented CD166 expression specifically 
restricted to SAN-like precursors during ESC in vitro differentiation, since CD166+ 
cells share the characteristic of gene expression of the SAN cells. To support these 
results, we investigated whether CD166 expression may recognize pacemaker 
precursors also in vivo, during mouse embryonic development.  
Here we show CD166 expression pattern in mouse forming heart at embryonic 
day 10.5 and 12.5. At these days the prospective atria and ventricles are 
recognizable, as well as the atrio-ventricular canal and the sinus horn, as shown in 
figure 14 (A-D). The precursors of the SAN and of the conduction system can be 
identified by the expression of HCN4 pacemaker channel, as already 
demonstrated in the literature36. Therefore, we compared the expression pattern of 
CD166 and HCN4, to understand whether they co-localize, meaning that are 
expressed by the same cells. At day 10.5, CD166 and HCN4 signals are almost 
totally overlapped (Figure 14, B-C). Thus, at this stage CD166 seems to be 
expressed in the cells that will originate the SAN. At day 12.5 instead, although 
still co-localizing with HCN4 in the prospective SAN region, CD166 expression 
results pronounced in the ventricles, which are HCN4-negative (Figure 14, E-F) 
and also in some extracardiac tissues and organs, such as the laryngo-tracheal 
groove, the mid gut, the esophagus, the carotid artery and the descending thoracic 
aorta (Figure 15). These data confirm that CD166 can be used as a transient 
selection marker for pacemaker cells at early stages of development. 
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Figure 14: CD166 expression in the developing cardiac conduction system.  
Hematoxilin and eosin staining of embryonic day 10.5 (A) and embryonic day 12.5 (D) hearts. 
Confocal images of adjacent slices of embryonic day 10.5 (B, C) and embryonic day 12.5 hearts 
(E, F) showing the expression of CD166 (green) and HCN4 (red) proteins. Nuclei stained by 4',6-
diamidino-2-phenylindole (DAPI) (blue). Calibration bar, 200 μm. Avc, atrioventricular canal; la, 
left atrium; lv, left ventricle; ra, right atrium; rscv, right superior caval vein; rsh, right sinus horn; 
and rv, right ventricle. 
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Figure 15: CD166 expression in extracardiac tissues 
Confocal images obtained from slices of E10.5 (A,B) and E12.5 (C;D) embryos showing the 
expression of CD166 (green) in extracardiac tissues/organs. Ltg, laryngo-tracheal groove; mg, mid 
gut; e, esophagus; rcca, right common carotid artery; dta, descending thoracic aorta 
HCN channels and calcium channels are present and contribute to action 
potential generation in CD166-selected cells 
HCN channels play a pivotal role in slow diastolic depolarization phase, 
consequently are important for the pacemaker profile of action potentials and thus 
for the auto-rhythmic activity. HCN1 and HCN4 are the isoforms mostly expressed 
in the SAN and the expression of HCN2 is sufficient to induce spontaneous 
activity when injected in the left atrium96. Therefore, to functionally characterize 
CD166+ cells, we evaluated the expression of HCN channel at protein level at 
different stages of culture.  
After 1 week of culture HCN1 and HCN4 are both expressed in CD166+ cells 
together with the cardiac marker α-actinin (Figure 16, A-B-C, D-E-F). Instead the 
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HCN2 signal, which has been shown to be the isoform expressed mainly in the 
ventricles113, was not observed in CD166+ (Figure 16, G-H); neonatal rat ventricular 
cardiomyocytes were used as a positive control (Figure 16I).  
 
Figure 16: HCN channel expression in CD166-selected cells after 1 week of culture. 
Confocal images of CD166-selected cells after 1 week of culture, labeled with the cardiac protein 
α-actinin (α-act, green) and the various HCN isoforms (red). Neonatal ventricular myocytes were 
used as positive control for HCN2 staining (I, red). Nuclei were stained with DAPI (blue). 
Calibration bars, 50 μm. 
After 3 weeks of culture CD166+ cells assume characteristics that make them more 
similar to adult SAN cells, in agreement with the gene expression analysis 
performed before. Firstly, the morphology of CD166+ cells results very similar to 
that of SAN cells in culture (Figure 17, A-B). From immunofluorescence staining 
we can notice that they still express HCN4 protein and, as the mature SAN 
cardiomyocytes, the expression of this channel co-localize with the expression of 
caveolin-3 (cav3) (Figure 17, C-D-E), which determines the formation of functional 
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membrane microdomains7. In addition, the expression pattern of HCN4 
expression in 25-day-old CD166-derived aggregates resembles that observed in 
adult SAN slices (Figure 17, F-G).   
 
Figure 17: HCN4 channel expression in CD166-selected cells compared to SAN cells. 
Phase contrast images of a single CD166-derived cell 25 days after cell sorting (A) and of an 
acutely dissociated mouse sinoatrial node cell (B). C-E: Confocal images of CD166-selected cells 
after 3 weeks in culture, labeled with either the cardiac protein caveolin-3 (cav-3, green) and 
HCN4 (red). Nuclei were stained with DAPI (blue). Calibration bars, 50 μm. Confocal images of 
a 25 day-old CD166-selected cell aggregate (F) and of a mouse SAN slice (G) labeled with an 
antibody anti-HCN4 (red). Nuclei were stained with DAPI. Calibration bars 50 μm. 
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These data show that HCN channel isoforms characteristic of the SAN are 
expressed in CD166-selected cells. However, this is not sufficient to affirm that 
these channels are also functional. For this reason, we also analyzed the If current 
by electrophysiological measurements, at the same stages of culture considered 
before (1 week and 3 weeks). We were able to record the If in cells of both stages 
of maturation, demonstrating that the expressed HCN channels are also active 
(Figure 18A). Furthermore, we compared the properties of the If current recorded 
from CD166+ cells with that recorded from adult SAN cells. From the current 
traces recorded we generated the activation curves and compared the voltages of 
half activation (Figure 18B). In 1-week-old CD166-derived cells the V1/2 was -
77.4±2.4 mV, while in 3-week-old cells it was -73.4±1.2 mV. These values were 
similar to that of native mouse SAN cells, which presents a V1/2 of -73.6±1.4 mV.  
 
Figure 18: Functional comparison of If current between CD166-selected cells and SAN myocytes.  
(A) Representative If traces recorded from single CD166-selected cell after 1 week in culture; (B) 
Mean activation curves obtained from CD166-selected cells after 1 (filled circles) and 3 weeks 
(open circles) in cultures and from mouse SAN myocytes (open squares); lines represent the best 
fitting by the Boltzmann equation. 
Other channels important for the generation of pacemaker action potentials are the 
calcium channels. Specifically, in mouse SAN L-type calcium channels are 
responsible together with Na+ channels for the fast depolarization phase while T-
type calcium channels contribute to the final part of the slow diastolic 
depolarization phase. Thus, we evaluated their contribution to the spontaneous 
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activity of CD166-selected cells cells.  During action potential recordings, we 
superfused alternatively the L-type calcium channel blocker nifedipine (0.1 μM) or 
the T-type calcium channel blocker Ni2+ (50 μM). The partial block of these 
calcium currents is expected to produce an overall decrease in the firing rate. The 
effect of both blockers on the spontaneous activity of CD166-derived cells is shown 
in figure 19A. The treatment with nifedipine and Ni2+ caused on average a rate 
decrease of 16.9±6.4% and of 17.7±2.6%, respectively. Interestingly, these reductions 
were comparable to those obtained with the perfusion of same blockers on mouse 
SAN cells (Figure 19B), where the nifedipine caused a decrease in the rate of 
16.5±2.2% and Ni2+ caused a decrease of 21.6±7.5%. These data show that calcium 
channels are functionally active in CD166-selected cells and their contribution is 
comparable to that of the same channels in SAN cardiomyocytes. 
 
Figure 19: Functional comparison of action potentials between CD166-selected cells and SAN 
myocytes.  
Representative action potentials recorded from CD166-selected cells (A) and SAN cells (B) in 
control (Tyrode) and during superfusion of either 50 μMNi2+ or 100 nM nifedipine. 
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The spontaneous activity of CD166-selected cells is maintained in culture for long 
periods (3-4 weeks), as observed in the previous part of this study. Here, after 
recording action potentials at different stages of culture, we found that on average 
CD166+ firing rate increases during time in culture (Figure 20), starting from 
approximately 1.5 Hz at 2-4 days in culture and reaching 6 Hz at 20-22 days. This 
increase in the rate is similar to that occurring during mouse embryonic 
development136 and is thus consistent with a maturation of the CD166-derived 
cardiomyocytes. 
 
Figure 20: Autorhythmic activity of CD166+-derived cells.  
Mean rate calculated from spontaneously beating CD166-selected cells at different time points in 
culture; insets show representative action potential traces. 
CD166-selected cells are able to respond to nervous system stimuli 
An important feature of the SAN is the ability to respond to autonomic nervous 
system stimulation, so that the heart rate can be modulated depending on the 
situation or condition that the body is experiencing. This modulation is achieved 
thanks to the activation of the signal transduction pathway initiated by the 
adrenergic and muscarinic receptors expressed on the plasma membrane of SAN 
cardiomyocytes. To investigate whether these receptors are also present on CD166-
selected cells, we double-stained them with anti-β1-adrenergic, anti-β2-adrenergic, or 
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anti-M2-muscarinic receptors together with the cardiac markers cav3 or α-actinin. 
The confocal images shown in Figure 21A demonstrate that these  receptors are 
indeed expressed. Then we further investigated the response ability by analyzing 
the rate response to perfusion of the  β-adrenergic agonist, isoprotenerol (1 μM), or 
of the muscarinic agonist, acetylcholine (0.1 μM). We recorded the spontaneous 
action potentials and found that upon isoprotenerol treatment the firing rate 
increased on average by 56.9±8.0% (n=5) while upon acetylcholine treatment it 
decreased by 22.9±5.4% (n=3), compared to the rate of the same cells in the control 
solution (Figure 21B).  
 
Figure 21: Autonomic modulation of the activity of CD166-selected cells. 
(A) Confocal images showing coexpression of caveolin-3 with β1-adrenergic and β2-adrenergic 
receptors and of α-actinin with M2 muscarinic receptors. Nuclei were stained with DAPI. 
Calibration bars,50 μm. (B) Spontaneous action potentials recorded during control and during 
perfusion of 1 μmol/L isoproterenol (Iso) and 0.1 μM acetylcholine (Ach) from CD166-selected 
cells; the bar graph shows the mean rate changes caused by the autonomic agonists. 
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CD166-selected cells can connect to and pace co-cultured neonatal 
ventricular cardiomyocytes 
To definitively identify CD166-selected cells as SAN-like cells, they need to really 
function as a pacemaker, that is they should be able to connect to and pace an 
excitable cardiac substrate. We evaluated the pacemaker ability of CD166-selected 
cells by co-culturing them with neonatal rat ventricular cardiomyocytes (NRVMs). 
We plated NRVMs either on top of aggregates derived from CD166+ or CD166- 
cells. In the same dishes, part of the NRVM were plated alone, not in contact with 
CD166-selected cells (Figure 22A). 
To test whether CD166-selected cells can connect to NRVMs, we evaluated 
connexin 43 (Cx43) expression in the co-cultures. We used ESC engineered clones 
expressing the GFP under HCN4 promoter, so that CD166-selected cells were 
recognizable from the co-cultured NRVMs. Cx43 (red) and GFP (green) staining 
shown in figure 22B demonstrates that Cx43 is expressed both in GFP- NRVM and 
GFP+ CD166-selected cells, in particular at the cell-to-cell contact points (white 
arrows). This suggests that these cells are able to connect to each other.  
After 3-4 days of coculture, necessary to form proper cell-to-cell electrical 
connections, action potentials were recorded. Figure 22C shows representative 
traces recorded from NRVMs alone or from NRVMs in co-culture with CD166+ 
cells. It is evident that NRVMs co-cultured with CD166+ cells have a higher and 
more regular rate than NRVMs cultured alone. The firing rate remained instead 
slower and more irregular in NRVMs co-cultured with non-beating CD166- cells 
(data not shown). On average, NRVMs in co-culture with CD166+-derived cells 
had a rate of 1.7±0.19 Hz (n=5), while NRVMs cultured alone or with CD166—
derived cells presented a significantly lower rate, on average 0.84±0.09 Hz (n=7) 
and 0.82±0.17 Hz (n=6), respectively. This higher rate demonstrate the capacity of 
CD166+ to drive the rate of the NRVMs. 
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Figure 22: Co-culture of CD166-selected cells and NRVMs. 
(A) Cartoon of the co-culture system, with NRVMs plated on either CD166- or CD166+ cells or in 
a distal area of the dish. (B) Confocal images of NRVMs cultured alone (left) or in co-culture with 
CD166-selected cells (right) stained for Cx43 (red). CD166-selected cells are also stained for GFP. 
White arrows indicate the cell-to-cell contact point. Nuclei were stained with DAPI. Calibration 
bar 10 μm. (C) Spontaneous action potentials recorded from NRVMs cultured alone (left) or in 
co-culture with CD166-selected cells (right) in control solution.  
CD166 is expressed in differentiating human iPSCs 
Even though the data collected so far clearly demonstrate that it is possible to 
generate SAN-like cells from mouse ESC, the main challenge of our study is to 
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translate this selection strategy to a human substrate, determining whether CD166 
is a good marker also for human SAN precursors.  
First of all, we started a collaboration with the group of Prof. Dell’Era from 
University of Brescia, in order to obtain a pluripotent human substrate, the hiPSCs.  
We performed in vitro cardiac differentiation of hiPSCs, following the spontaneous 
differentiation protocol23 (Figure 23A). We obtained auto-rhythmic beating clusters 
and were able to keep them in culture for long periods (from 30 to 60 days). The 
mature hiPSC-derived cardiomyocytes were characterized for the expression of 
cardiac markers, such as α-actinin and cardiac troponin (Figure 23B).   
 
Figure 23: Cardiac differentiation of hiPSCs. 
(A) Schematic time-course of the hiPSC differentiation protocol. Beating cluster are seen starting 
form day 12. (B) Confocal images of hiPSC-derived cardiomyocytes stained with α-actinin (red) or 
cardiac troponin T (green). Nuclei were stained with DAPI. 
We then investigated the expression of human CD166 in our in vitro system. 
Although CD166 is expressed in human ESC- and iPSC-derived 
cardiomyocytes61,105, in human fetal heart61 and during endodermal differentiation 
of hiPSCs, its expression at different stages of spontaneous iPSC cardiac 
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differentiation has not been described. For this reason, we evaluated here by flow 
cytometry the percentage of CD166-positive cells during  hiPSC in vitro 
differentiation.  
We started analyzing the undifferentiated hiPSCs and found high percentage of 
CD166+ cells (64,9%). Figure 24A shows an example of the cell sorting. We then 
evaluated the percentage of CD166+ cells at different days of differentiation. From 
a first analysis it appears that a decrease of CD166+ cells during the early days of 
differentiation occurs (day 11 = 12,7±4,7%), while afterwards a progressive increase 
can be observed (day 15= 21,7% day 20 = 25,4%; day 34 = 38,4±0,8%) (Figure 24B). 
This seems comparable to what occurs in mouse ESC differentiation, suggesting 
that the early days may be the more suitable for the selection of pacemaker 
precursors.  
In any case, these are preliminary results and we need to evaluate in CD166+ cells 
also the expression of a cardiac marker, such as α-actinin, to better identify the 
proper selection day.    
 
Figure 24: Flow cytometry analysis of CD166+ cells during hiPSC differentiation. 
(A) Representative dot plot from flow cytometry analysis of dissociated EBs, showing CD166- 
(black, P4) and CD166+ populations (green, P5) at day 15 of hiPSC cardiac differentiation. (B) Bar 
graph displaying the mean percentage of CD166+ cells in undifferentiated hiPSCs and at different 
days of differentiation. 
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DISCUSSION 
The isolation of stem cell-derived cardiomyocytes sharing the characteristics of 
SAN cells appears of great relevance for different reasons. One important 
application is the generation of a cell substrate that can be implanted in patients, 
pace resident cells and restore the correct heart rhythm; that is the biological 
pacemaker. This results a particularly actual issue firstly because the electronic 
pacemaker currently in use present several still unresolved limitations39,46. Besides, 
the implantation rate of electronic pacemaker is growing in the recent years and is 
expected to further grow in the next years due to population ageing. Importantly, 
a biological pacemaker generated through this cell-based strategy not only can 
integrate in the tissue better than an electronic device, but also avoids 
modifications in the cell genome of the patient, thus it appears more controllable 
and suitable for clinical applications.  
Another advantage arising from isolation of stem cell-derived pacemaker cells is 
the possibility of in vitro studies on autorhythmic mature cells that can be kept in 
culture for long periods, in order to test drugs acting on cardiac rhythm.   
Because stem cell differentiation give rise to cells at various stages of differentiation 
and also at different cell types7, one of the major challenges in obtaining a 
homogeneous population of stem cell-derived pacemaker cells is the selection 
method. 
Previously, other researchers had attempted selecting SAN-like cells upon ESC 
differentiation, using HCN4 as a marker. This channel mediates the If current 
which is the main responsible for the slow diastolic depolarization phase of SAN 
cell spontaneous action potentials. Although HCN4 is expressed at high levels in 
SAN cells, extracellular antibody against this channel are not available. Thus, the 
selection of HCN4+ living cells must involve a manipulation of cell genome, as 
performed in the study of Morikawa et al.. engineering ESCs for the expression of 
EGFP under HCN4 promoter81. Moreover, HCN4 is not only expressed in SAN 
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precursors but also in neuronal cells36, and indeed in the same study the 65% of the 
HCN4-selected population expressed the neuronal marker Nestin and, not 
surprisingly, lacked spontaneous beating81.  
A more recent attempt of pacemaker cell selection used TBX3 overexpressing 
ESCs stably transfected with antibiotic resistance under Myh6 promoter50. Notably, 
Myh6 is the atrial-specific isoform and it was shown not to play a fundamental role 
in conduction system formation33, thus this selection method appears controversial. 
Nonetheless, this antibiotic-based selection yielded 80% of pacemaker 
cardiomyocytes, stable in culture for several weeks50. However, also in this study 
they used engineered cells, which are less appropriate for clinical applications.  
Although very useful for in vitro studies, these data underlie  the need of 
alternative selection methods to build a biological pacemaker that can be really 
addressed to humans. A promising approach is based on endogenous cell surface 
markers expressed during stem cell differentiation. Until now, two markers have 
been shown to be expressed both in the developing heart and in ESC-derived 
cardiomyocytes: CD166 (or ALCAM)61,105,109 and CD172a (or SIRPA)29. SIRPA is 
however expressed also in the adult heart, in both atria and ventricles, ruling 
against its possible use as a selection marker for pacemaker cells.   
Here we selected pacemaker cells based on CD166 expression. This molecule has 
been previously used to select cardiovascular precursors from yolk sac, observing 
that cardiac cells originate from CD166+/Flk1- precursors84. In agreement with this 
evidence, our CD166+ cells did not express Flk1109. Recently, Rust et al. used 
CD166 to enrich in cardiomyocytes human ESC-derived cells105. They affirmed 
that the CD166-selected cells present an embryonic phenotype based on ion 
channel and structural protein expression, while our data on CD166+ cells showed 
that they exhibit functional features of mature SAN cells (Figure 1). 
We observed in CD166-selected cells maintained in culture for 3 weeks a 
morphology similar to SAN cells and the expression of the SAN-restricted HCN4 
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isoform not only at transcript but also at protein level, with a pattern similar to that 
found in the adult SAN (Figure 17).  
The capability to generate SAN-like action potentials was then demonstrated by 
the functional presence of the main currents characterizing the heart conduction 
system. If current was recorded and its activation curve completely overlapped the 
one obtained in mouse SAN cells (Figure 18). This current can be also modulated 
by nervous system, thanks to the expression in our CD166-selected cells of β-
adrenergic and muscarinic receptors, whose activation causes the stimulation or 
inhibition of cAMP synthesis respectively. The cAMP binding modifies HCN4 
open probability influencing slow diastolic depolarization phase and thus firing 
rate17. Indeed we observed in CD166-selected cells an increase or a decrease in 
firing rate after adrenergic or muscarinic agonist administration, respectively 
(Figure 21). The effects observed are comparable to the effects reported in the 
literature on mouse SAN cells3. Furthermore, functional presence of ICaL and ICaT 
currents, involved in the slow and fast depolarization phases of pacemaker cell 
action potential, was observed following the administration of their respective 
blockers causing a decrease in firing rate, totally similar to that produced in the 
SAN cells (Figure 19).  
Beside sharing characteristics of the SAN profile, the action potential firing of our 
CD166-selected cells also increased in the rate during time in culture, further 
attesting the maturation of CD166+ cells (Figure 20). Importantly, we also 
demonstrated that our CD166-selected cells are able to electrically connect with 
other excitable cells and are also able pace other cells in co-culture imposing their 
faster beating rate, thus playing the pacemaker role similarly to the SAN (Figure 
22).  
These features are compatible only with a differentiated and mature phenotype. In 
agreement with this, our CD166+ cells present negligible levels of proliferation and 
did not form teratomas in vivo. Instead, the CD166-selected cells of Rust et al. 
showed a high proliferation rate (20-30%)105. The clear differences between the 
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result of our selection and that of Rust et al. can derive from the different protocols 
used. In particular, their selection was operated at the peak of CD166 expression, 
while our selction was done at the differentiation day corresponding to the peak of 
α-actinin expression in CD166+ cells. Notably, data from the literature showed that 
CD166 is specific for cardiomyocytes only in a determined time-window43,84. Here 
we have further strengthened this concept showing that in mouse embryos CD166 
is co-expressed with HCN4 in the prospective SAN by embryonic day 10.5, but by 
day 12.5 CD166 expression broadens also to other regions and organs (Figure 14). 
Therefore, it appears important to compare CD166 expression with that of a 
cardiac marker, as we did using α-actinin, in order to avoid contamination of other 
lineage precursors. Nevertheless, the work of Rust et al. importantly showed that 
CD166 is expressed during hESC cardiac differentiation, thus opening the 
prospective of using this marker to select pacemaker cells also from human EBs.  
More recently, also Lin et al. have used CD166 for cardiomyocytes selection 
during human stem cell differentiation61. They analyzed the expression of CD166 
at mRNA level during hiPSC differentiation and showed that CD166 is expressed 
in undifferentiated hiPSCs, the expression decreases at the beginning of 
differentiation, increasing again by differentiation day 6 and remaining almost 
constant for the rest of the differentiation protocol. Lin et al. selected 
cardiomyocytes at differentiation day 20, when atrial and ventricular markers were 
already expressed, thus the differentiation was already advanced to the working 
myocardium fate.  
Here we assessed whether through an early selection of CD166+ cells it is possible 
to obtain pacemaker precursors, thus translating our isolation method 
accomplished in mouse cells to a human substrate. Clearly the possibility to isolate 
human SAN-like cells would be of great interest and would be a step forward in 
the project of generating a feasible biological pacemaker with clinical applications. 
We differentiated hiPSCs into cardiomyocytes following the spontaneous 
differentiation protocol (Figure 23). Analyzing CD166+ cell percentage during 
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differentiation, we also found  high fraction of CD166-expressing hiPSCs (64,9%). 
At day 11 of differentiation however the percentage of CD166+ cells appears much 
lower (12,7%). This seems comparable to the trend of CD166 mRNA levels found 
in the initial phase by Lin et al.61. However, the differentiation protocol used by 
Lin et al. did not consist in a spontaneous differentiation through EB formation, 
but differentiation was induced adding specific factors to the culture medium and 
operating various subsequent selection steps by flow cytometry. These differences 
in protocol method and timing cannot permit a proper comparison. Notably, 
although Lin et al. protocol results much less time-consuming, forcing the 
differentiation toward cardiovascular cell types may produce disadvantages as well. 
Possibly, the differentiating cells could maintain for shorter time the primitive 
phenotype of pacemaker precursors, thus the proper time-window for CD166-
based pacemaker cell isolation may result anticipated or reduced. For these 
reasons, we consider more suitable for our aims to use the spontaneous 
differentiation protocol.  
From day 11 of our differentiation protocol, the percentage of CD166+ cells 
increased steadily and at day 34-40 of differentiation it was approximately 40%. 
This increasing of CD166+ fraction is consistent with the trend previously observed 
during mouse ESC differentiation (Figure 1). The percentage of CD166+ cells at 
the day of selection in mouse cells was around 10-15%. Here during hiPSC 
differentiation, a similar percentage was observed at day 11-12. We can then 
speculate that day 11-12 may represent a suitable day for pacemaker precursors 
selection during hiPSC differentiation. Anyway, to better identify a suitable 
selection day based on CD166 expression we believe that it would be important to 
evaluate also a cardiac marker expression, as pointed out before. Unfortunately 
this was not possible in the experiments performed here, due to the less efficient 
differentiation of hiPSCs compared to that of mouse ESCs, producing not enough 
cells for subsequent gene expression analysis. Next experiments will focused on 
increasing the amount of cells available upon differentiation. In addition, it remains 
 
62 
 
to be elucidated whether the human CD166-selected cells are able to re-aggregate 
and spontaneously beat in culture after the cell sorting, as did mouse CD166+ cells. 
In conclusion, with this study we functionally characterized mouse CD166-selected 
cells, showing that they behave like SAN cells, are able to respond to autonomic 
stimulation and are able to act as a pacemaker in vitro. We also began using a 
human cell substrate, with the aim of adapting our selection protocol on human 
differentiating iPSCs. Showing that CD166 is expressed during differentiation not 
only of mouse ESCs but also of hiPSCs opens the possibility to isolate hiPSC-
derived pacemaker cells, that can be really used for the generation of a patient-
specific biological pacemaker.     
  
 
 
 
 
PART II:  
 
FUNCTIONAL ANALYSIS OF M54T MIRP1 MUTATION FOUND IN A 
PATIENT WITH IDIOPATHIC EPILEPSY 
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FOREWORD  
Aim and relevance of the project 
This project aims to find and functionally characterize genetic mutations in 
idiopathic epileptic patients, in order to provide mechanistic explanation of the 
disease and possibly test specific treatments for reverting the functional effects. 
Remarkably, the idiopathic epilepsy is the form associated with a genetic etiology64, 
thus the phenotype of these patients is probably due to some mutations in their 
genome. Although some mutations have been related to epilepsy, none of them 
showed a co-segregation with the pathological phenotype, thus further 
investigations are needed to identify the causative dysfunction leading to the 
disorder.  
In this project, we focused in particular on HCN channels as candidates to be 
altered in epileptic patients, since there are more and more evidence in the 
literature linking these channels to epilepsy25,28,65,85,108,119. Few years ago our group 
started a genetic screening on a population of 185 patients affected by idiopathic 
generalized epilepsy and 209 controls, analyzing both HCN channel and their 
accessory protein genes (caveolin3, MiRP1, TRIP8b, filamin A) . In this study only 
patients who had a familiar history of epilepsy were enrolled. After the screening, 
we selected mutations  that caused a non-synonymous aminoacid variation in the 
protein. From this screening emerged for example the novel mutation E515K in 
the HCN2 gene. The electrophysiological characterization revealed that the E515K 
mutation had a loss of function phenotype caused by a large negative shift of the 
channel’s activation, outside the physiological range of voltages. Expression of the 
wt or the E515K mutant in rat neonatal neurons demonstrated also that the 
mutation significantly increased membrane excitability28.  
During the last year of my PhD I have analyzed the functional effect of the M54T 
mutation of MiRP1 on HCN channel properties and more generally on neuronal 
excitability. This mutation was indeed found in heterozygosis in a patient with 
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idiopathic generalized epilepsy and in her daughter, who was affected by febrile 
seizures (Figure 25). The M54T mutation involves the transmembrane region of the 
peptide, causing a change from a nonpolar to a polar aminoacid. This mutation 
was previously found by Nathawe et al., in a cardiopathic individual with Long-QT 
syndrome and sinus bradycardia. Because of the known interaction of MiRP1 with 
HCN channels and the bradycardia, they focused their attention on the effects of 
M54T MiRP1 on HCN channels, co-expressed in neonatal cardiomyocytes.  
Nathawe et al. showed that M54T mutation caused a 80% decrease in HCN4, but 
not HCN2, current density and caused also a slowing in the activation kinetics of 
both HCN4 and HCN286 only in a restricted range of voltages.  
 
Figure 25: M54T mutation in a family genetic tree. 
The scheme shows women as circles and men as squares. The arrows indicates the proband. In 
green the individuals affected by some form of epilepsy. The filled circle identifies individuals 
carrying M54T mutation.   
Because it is known from the literature that MiRP1 deletion in the brain causes 
alteration of HCN channel properties and increases neuron excitability, we 
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hypothesized that the functional interaction of M54T MiRP1 with HCN channels 
could be possibly involved in the generation of the epileptic condition.  
For these reasons, we decided to functionally analyze the effects of M54T MiRP1 
mutation, and especially the possible effect on HCN2 and HCN4 channels 
properties. The strategy was to overexpress HCN channels and the WT or mutated 
MiRP1 in a heterologous cellular system previously used to assess the functional 
effect of MiRP1 on HCN channels, and then to analyze the electrophysiological 
properties of HCN2 and HCN4 currents. Among HCN channel isoforms, we 
considered HCN2 and HCN4, because an effect of the mutation was already 
observed on these channels86; besides, HCN2 is the most expressed in the brain, 
while HCN4 plays a pivotal role in the thalamic oscillations10,110.   
Since the effects of MiRP1 as accessory subunit have been shown to vary 
significantly depending on the cell type used, we subsequently assessed the effect 
of the mutation in a neuronal context. Here we also evaluated the effect of the 
mutation on neuronal excitability.  
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INTRODUCTION 
The HCN channels in the central nervous system 
HCN channels are cation channels activating upon membrane hyperpolarization, 
as already described in the first part of this thesis. They are expressed not only in 
the heart but also, importantly, in the central nervous system (CNS). In particular, 
in the brain HCN1 is found in the neocortex, in the cerebellar cortex, in the 
hippocampus and in the brain stem; HCN2 is expressed almost ubiquitously in the 
brain, but especially in the thalamus and in the brain stem nuclei. HCN4 
expression is instead generally low in the CNS, except for the thalamic nuclei and 
the olfactory bulb, where high levels are found80,89,107,110.  
The If current mediated by HCN channels is also called Ih in the CNS, because of 
its activation in hyperpolarization. In the brain, it was first discovered in 
hyppocampal pyramidal neurons and named initially “queer” current40 (Iq). Also in 
some regions of the CNS, such as in thalamocortical neurons, in the inferior olive 
neurons of the brainstem and in hippocampal striatum oriens interneurons, Ih can 
act as a pacemaker current, thus inducing spontaneous activity99. In the 
thalamocortical neurons, regularly spaced short firings are observed when they are 
hyperpolarized, in physiological condition during non-REM sleep or in 
pathological condition during absence seizures8. This action potential profile is 
named the “burst mode” and has been associated to a decrease transfer of 
information to the cortex115. In this mode, the activation of Ih by hyperpolarization 
sustains the phase of slow depolarization that activate T-type calcium channels, 
which in turn further depolarize the membrane reaching the threshold for action 
potential firing (Figure 26). The consequent inactivation of T-type calcium channels 
terminates the spike and since at those voltages HCN channels are closed, a 
subsequent hyperpolarization occurs, which in turn leads to the re-opening of HCN 
channels and therefore to the begin of another cycle. Interestingly, HCN2 KO 
mice have a higher susceptibility to fire in the burst mode upon an excitatory input, 
than wild-type animals65, possibly because they have a more hyperpolarized resting 
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membrane potential (RMP); this implies that less T-type calcium channels are in 
the inactive state and thus they are more easily activated10. 
 
Figure 26: Firing mode of thalamocortical neurons. 
The upper panel shows recording of thalamocortical action potentials. The panel below shows an 
higher temporal resolution of thalamocortical firing, indicating the currents involved. (from Biel et 
al. 2009) 
In other cells of the CNS that are normally inactive, the Ih is not responsible for the 
generation of the action potentials but its properties make it fundamental in the 
control of membrane excitability, in stimuli responsiveness and in the control of 
neuronal networks8,10 activity. Specifically, Ih plays two main roles in neurons: it 
contributes to set the RMP and it controls its oscillations. Indeed, HCN channels 
are partially open at voltages near the RMP, thus they mediate a tonic inward 
depolarizing current influencing the membrane potential91 (Figure 27). Though an 
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inward depolarizing current is by definition an excitatory current, since it brings 
the RMP closer to the firing threshold, the constitutively activated Ih lowers at the 
same time the membrane resistance91; therefore, following the Ohm’s law, for a 
given current input, the variation of membrane potential is smaller than it would 
be in the absence of Ih
10, resulting in an inhibitory effect. Thus, Ih plays a dual role 
in determining neuron excitability30. The effect on a single-neuron excitability 
depends on the balance between the depolarized RMP and the input resistance (or 
membrane resistance), which in turn is affected by other intrinsic properties, such 
as neuron type, developmental stage and neuromodulation30.  
 
Figure 27: Main roles of the Ih in the neurons.  
The graph illustrate the Ih activation curve, showing in particular that at voltages near RMP the 
open probability of HCN channel is >0. HCN channels mediating a depolarizing current have 
both an excitatory effect increasing RMP and an inhibitory effect decreasing membrane resistance. 
(adapted from Biel et al 2009) 
Another function of HCN channels concerns the control of RMP oscillations, 
counteracting both excitatory and inhibitory subthreshold stimuli: this means that 
when an inhibitory hyperpolarizing input arrives, a greater fraction of HCN 
channels opens, causing a depolarization back toward the the original RMP. This is 
called the “depolarizing voltage sag” (Figure 28A). On the other hand, an 
excitatory depolarizing input produces a progressive increase in the fraction of 
closed HCN channels, thus determining the loss of the tonic depolarizing Ih, 
leading indirectly to a ripolarization of membrane potential toward its initial resting 
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value. Thus, Ih can also generate the “hyperpolarizing voltage sag” effect
10 (Figure 
28B).  
 
Figure 28: Ih actively opposes changes in membrane voltage.  
Cartoon of a current-clamp experiment in a neuron. In the presence of Ih (black traces), a 
hyperpolarizing current step induces a depolarizing voltage sag (arrow, A) and a depolarizing 
current step induces a hyperpolarizing voltage sag (arrow, B). Blockade of Ih by cesium eliminates 
the sag (red traces). 
The reduction of membrane resistance caused by Ih reflects in the dendrites an 
increase in the amplitude attenuation of EPSPs. EPSPs spreading from the 
dendrites to the soma normally degrade over distance along neuron membrane. 
Since the passive propagation of the electric stimulus from a dendrite to the soma 
depends not only on intracellular resistance and membrane capacitance, but also 
on membrane resistance, the presence of Ih that lowers membrane resistance 
causes further EPSP attenuation (Figure 29). This effect is very relevant for the 
control of the process of dendritic integration. Indeed, single EPSPs are too weak 
to reach the action potential threshold at the trigger cone, thus several EPSPs must 
be integrated in order to  generate an action potential. Logically, one could expect 
the temporal summation of distal EPSPs to be greater than that of proximal EPSPs. 
Instead this is not the case thanks to Ih, because HCN channel expression follows a 
somato-dendritic gradient (Figure 29), thus Ih density is higher in the distal rather 
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than in the proximal dendrites, dampening with a larger extent the distal inputs66. 
As an important consequence, the effects of EPSP become independent to their 
location127.  
 
Figure 29: The somato-dendritic gradient of HCN channel expression. 
The cartoons shows the somato-dendritic gradient of Ih normalizing localization dependence of 
temporal summation. Summation of EPSPs from proximal (black trace) and distal (gray trace) 
dendrites recorded at the soma after propagation. The voltage recordings are shown before (top 
panel) and after (bottom panel) inhibition of Ih by the selective blocker ZD 7288. (adapted from 
Biel et al 2009) 
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Epilepsy and HCN channels 
HCN channels dysfunctions has been associated mostly with cardiac diseases, due 
to mutations in the HCN4 gene. In the CNS also, acquired alterations of HCN1 
and HCN2 channels, have been associated with pathological conditions, such as 
subarachnoid hemorrhage8,60, neuropathic pain32 and notably epilepsy. 
Epilepsy is a condition or a group of conditions involving transient disorders in 
cerebral function caused by the occurrence of abnormal firing burst of large 
population of neurons and characterized by recurrent seizures64. This effect is 
considered the result of an abnormal regulation of neuronal excitability that favors 
hypersynchrony88. It is the third most common brain disorder and approximately 
one third of the affected subjects do not respond satisfactorily to current 
treatments98. Epilepsy is divided into idiopathic, cryptogenic and symptomatic 
forms. Idiopathic epilepsy is the type in which the primary etiology is genetic, and 
can be generalized or focal (partial). The idiopathic generalized epilepsy includes 
the childhood and juvenile absence epilepsy, juvenile myoclonic epilepsy and 
epilepsy with grand mal seizures on awakening. The mutated genes that have been 
associated with these epilepsies largely involve voltage- or ligand-gated ion 
channels64,90 (Table 1). These epilepsies present a complex pattern of inheritance, 
suggesting an interaction of several susceptibility genes24,59.  
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Table 1: Genes associated with idiopathic epilepsies  
(from Santoro et al. 2003) 
The link of HCN channel alterations and epilepsy in animal models 
Initial evidences of HCN channel involvement in epilepsy came from rat models. 
Hyperthermic febrile seizure rat models presented regional changes in 
hippocampal HCN channel subunit expressions, with a down-regulation of HCN1 
and an up-regulation of HCN2 in the hippocampal CA1 neurons15. Other rat 
models, the Wistar Albino Glaxo rats bred in Rijswijk (WAG/Rij), which 
spontaneously develop seizures, presented a significant reduction of the Ih in 
pyramidal neurons, with a decreased levels only of HCN1 and not of HCN2116. 
This was associated both with a hyperpolarized RMP and an increase in temporal 
summation, facilitating dendritic burst firing, which can contribute to network 
excitability56,116. Moreover, another study showed that also the sensibility to cAMP 
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may contribute to the pathogenesis, as an increase in the cAMP-insensible isoform 
HCN1 was observed in thalamo-cortical neurons of these rats18.  
Another concrete evidence linking HCN channel dysfunction with the disorder 
was provided by KO mice. HCN2-KO mice display significant reduction of Ih in 
the thalamocortical neurons and thus a more hyperpolarized RMP, compared to 
the WT mice. Notably, HCN2-KO mice display spontaneous absence epileptic 
seizures65. Also the deletion of HCN1 produces a similar effects in mice108, 
although the seizures were not spontaneous.    
HCN channels dysfunctions in epileptic patients 
Among susceptibility genes for epilepsy in humans, HCN channels are found. 
Indeed, some mutations in HCN1 and HCN2 have been identified in patients 
affected by epilepsy. In particular, one study found a single HCN1 polymorphism 
in a patient and never in the healthy controls, and two non-synonymous mutations 
in HCN2119. One of these, a deletion of 3 proline in HCN2 gene, was observed 
also in another independent study, where they demonstrated through in vitro 
expression of the mutant channel that it causes an increase in the Ih
25. However, 
the effect on neuronal excitability was not investigated.  
Recently, a study of our group found the homozigous E515K loss-of-function 
mutation of the HCN2 gene in a patient with idiopathic generalized epilepsy, 
causing a large negative shift of HCN2 activation curve and slower activation 
kinetics in heterologous expression system; this was maintained also in rat neonatal 
cortical neurons, resulting in a strongly reduced contribution of Ih to activity which 
was associated with an increased neuron excitability compared to the WT28 (Figure 
30).  
Finally, through the new technology of high-throughput all-exome sequencing, a 
recent study found some de novo point mutations in HCN1 gene in patients with 
infantile epileptic encephalopathy85.  
In any case, all the mutations found in patients have not been found to co-
segregate with disease, thus they cannot be considered as causative of epileptic 
phenotype, but only a possible susceptibility trait92.  
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Figure 30: Increased neuron excitability in neurons transfected with E515K HCN2.  
Sample voltage traces recorded during injection of  10 –50 pA depolarizing current steps into 
neonatal rat cortical neurons. (from DiFrancesco et al 2011) 
Beside genetic screening, some studies focused on investigating the expression of 
HCN channel in human brain tissue, but they did not found differences in the 
transcript levels in epileptic patient compared to controls, except for the dentate 
gyrus, where high levels of HCN1 were found in patients. This was surprising since 
normally HCN1 is not expressed in that region of the brain9. Notably, in this case 
an upregulation was observed and not a loss of function.  
Another study analyzed neocortical neurons obtained from epilepsy surgeries and 
found a lower expression of Ih in patients with more frequent seizures compared to 
those with more sporadic ones. This suggested that a loss of HCN function may be 
associated with more severe forms of epilepsy125. However, no control comparisons 
were possible for this experiment. It must be noticed that these changes in the 
expression may be not the cause, but rather a compensatory response to abnormal 
excitability during  seizures8.   
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Is HCN channel alteration causative of epilepsy? 
From literature data it appears that epilepsy can be associated with both, up- and 
down-regulation of HCN channels and especially of HCN1, depending on the 
brain region10. This is consistent with the dual action of Ih on neuron excitability 
described before, which can result in an excitatory or inhibitory effect depending 
on the context30.   
Interestingly, in rat epilepsy model it was noticed that when seizures were 
chronically suppressed, the observed alterations in ion channels, including HCN1, 
were reversed12. This suggests that HCN channel deregulation in this model is not 
causative for epilepsy, but it can amplify the effect of spontaneous seizures92. On 
the other hand, it has been pointed out that HCN channel can have also a 
causative role69, since in rat models with pilocarpine-induced epileptic state the 
changes in HCN channels occur before the spontaneous seizures52. Ultimately, the 
mechanism of HCN channel alteration can be either dependent or independent on 
previous recurrent seizure. Thus, the increased neuronal excitability due to 
downregulation of dendritic HCN channel may be associated with both the trigger 
of epileptogenesis and maintenance of the epileptic state51. 
 
MinK-related peptide 1 (MiRP1) 
MiRP1, encoded by the gene KCNE2, is a member of the MinK(minimal K+ 
channel protein)-related protein family comprising 4 members, which are 
characterized by a single transmembrane peptide, with the C-terminus in the 
cytoplasm and the N-terminus placed in the cytosol70 (Figure 31). MiRP1 
expression has been found in the heart, especially in the SAN and Purkinje fibers, 
and in rat and human brain1,49,94, including the hippocampus, the thalamus and the 
hypothalamus121. 
MiRP1 is composed by 123 amino acids and was firstly discovered in the 1999 by 
Abbott and colleagues by homology-searching in the rat genome, showing that it 
can assemble with hERG potassium channel, acting as β-subunit and altering its 
properties, such as activation curve (shifted positively), kinetics of activation 
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(slower) and deactivation (more rapid). This assemble is necessary to generate the 
rapid delayed rectifier potassium current IKr
1.  
 
Figure 31: Schematic representation of the MiRP1 peptide. 
Although in this work no association with other tested potassium channels was 
found (KCNQ1, KCNQ2, Shaker, Kv1.3, Kv1.5, Kv1.6, Kv2.1)1, other works 
presented data showing the interaction of MiRP1 with Kv4.2135 and KCNQ1121. 
More recently, it has been demonstrated that MiRP1 associates with the complex 
KCNQ1-MinK and in ventricular myocytes causes the reduction of the mediated 
IKs current
49. The variety of the possible interaction of MiRP1 make it 
characterized by a promiscuity of functions. The molecular basis and specificity of 
MiRP1-ion channels interaction are largely unknown62 and studies are still ongoing 
investigating new possible interacting channels. Very recently, it has been shown 
that MiRP1 can also interact with L-type calcium channels, decreasing calcium 
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current magnitude in cardiomyocytes, although no effect was found in 
heterologous expression system62.    
Interestingly, it has been shown also that MiRP1 can interact with HCN channels, 
changing their expression and gating properties both in heterologous expression 
systems and in cardiomyocytes14,22,95,132. These effects are however isoform and 
species dependent. Notably, some researchers have questioned the regulatory 
properties of MiRP1 for HCN channels14,86, since lack of effects were observed 
upon co-trasfection of the peptide with the four isoforms of rabbit HCN channels 
in HEK cells4 or with human HCN2 and HCN4 in cardiomyocytes86.  
Given the expression of MiRP1 and HCN channels in the heart and in the brain, 
further investigations on the impact of MiRP1 on HCN isoforms may provide 
useful insights for the understanding and for therapeutic manipulation of rhythmic 
activity14. 
MiRP1 mutations and KO mice  
Inherited variants of MiRP1 gene have been found at the same time of its 
discovery and have been associated with cardiac diseases, in particular with 
congenital and drug-induced long-QT syndrome, via alteration of the rapid 
outward rectifying current IKr generated by its interaction with hERG
1. This 
probably arises from prolonged ventricular action potentials arising from reduced 
K+ flux2. The MiRP1 mutations included M54T, I57T, V65M and A116V1,47,112. 
The channels assembled with HERG and the human M54T MiRP1 showed a 
three-fold more rapid deactivation kinetics of this complex; V65M MiRP1 caused a 
slower activation and a more rapid inactivation of the channel; instead, A116V 
MiRP1 had the effect of decreasing current density1,47. These mutations were found 
also in patients with acquired arrhythmia subsequent to drug administration and a 
study demonstrated that the combination of the drug and the mutation led to long-
QT interval in these subjects112. Another mutation found by Abbott and collegues 
was then discovered to be a polymorphism present in 1,6% of the caucasian 
population of USA; it was however shown that ERG channels assembled with this 
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MiRP1 variant were more sensible to drugs acting as potassium channel blockers, 
thus this mutation can predispose to acquired cardiac arrhythmias112.  
Recently, Nathawe et al. found the M54T MiRP1 mutation in a patient with long-
QT syndrome and sinus bradycardia. They have shown that HCN channel 
properties expressed  in neonatal rat cardiomyocytes are altered by this mutation;  
in particular the M54T causes slower kinetics of activation of both HCN2 and 
HCN4 and a decrease in the current density of HCN4. This was the first evidence 
of an effect produced by MiRP1 mutation on HCN channels86. 
Thus far, the identified mutation in MiRP1 in humans have been associated only to 
cardiac diseases and then studied in vitro with functional analysis. 
MiRP1 function in vivo has also been studied using KO mice. These mice were 
firstly generated by the group of Abbott and the first phenotype identified involved 
gastric acid secretion. These mice were affected by achlorhydria, 
hypergastrinemica, gastric glandular hyperplasia100 and iron-deficient anemia106. 
The phenotype was caused an abnormal distribution of ERG in gastric glands. 
They showed also an impaired targeting of ERG and Kv1.3 to the choroid plexus 
epithelium (CPe) membrane, leading to an increase the anion secretion in the 
cerebrospinal fluid101. In subsequent study, they observed mice pubs and found 
that the thyroid hormone biosynthesis was disrupted, leading to hypothyroidism, 
alopecia and cardiac abnormalities such as hypertrophy, fibrosis and reduced 
fractional shortening102. Finally, they also showed that deletion of MiRP1 causes a 
delayed ventricular ripolarization in adult mice103, and deepening the analysis, a 
multisystem syndrome was observed, involving both cardiac and extra-cardiac 
tissue and metabolic disorders45.  
In recent years, another work investigated the effects of MiRP1 deletion focusing 
on HCN channels. Using brain slices of KO mice they found that MiRP1 deletion 
causes a negative shift in the Ih activation curve, a slowdown of the gating kinetics 
and a decrease in Ih current density. In addition, the expression of HCN1 and 
HCN2 channels was reduced in whole-brain extracts. As a result, an increase in 
input resistance and temporal summation was observed. Importantly, they found 
an overall increased intrinsic excitability with enhanced burst duration in 
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corticothalamic neurons, implying the presence of augmented excitatory input to 
the thalamus131.  
These effects suggest a functional interaction of MiRP1 with HCN channels in 
physiological condition, notably in the brain, supporting in vitro analysis on 
heterologous and cardiac expression systems. It is however important to mention 
that in this paper the author reported also that MiRP1 and HCN1 or HCN2 did 
not co-immunoprecipitate131, an evidence arguing against their interaction. Thus, 
further researches would be helpful to clarify HCN channel-MiRP1 interaction.  
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MATHERIALS AND METHODS 
Generation of wild-type (WT) hMiRP pIRES II plasmid 
The plasmid was built from pIRES II vector and cDNA encoding WT hMiRP. The 
latter was excised from a pCI-Neo vector, using the restriction enzyme EcoRI 
(FastDigest enzymes Fermentas™), and then moved to  into pIRES II vector which 
was cut with the same enzyme. WT hMiRP was inserted into the vector using T4 
Ligase (Thermo Scientific™). The correct insertion of the plasmid was verified by 
digestion with two enzymes (BamHI and NheI, FastDigest Fermentas) cutting one 
inside and one outside the inserted band, so that two bands of a determined length 
were visible in gel electrophoresis. The plasmid obtained was then amplified in 
DH5α competent bacterial cells (transformation protocol below). 
Generation of M54T mutated hMiRP pIRES II plasmid 
A QuikChange II XL Site-Directed Mutagenesis Kit (Agilent technologies™) was 
used with proper forward primer (5'-ccaatcatcaccgtgaggtacaggatgacatagtag-3') and 
reverse primer (5'-ctactatgtcatcctgtacctcacggtgatgattgg-3') to insert the TC 
substitution into WT hMiRP pIRES II corresponding to M54T mutation. 
Then DpnI was added, which digest only parental DNA because it recognises 
methylated region. Using specific competent bacterial cells (XL10 GOLD), the 
plasmidic DNA was amplified. 
PCR condition 
- H2O MilliQ      to 50 µμL 
- Reaction Buffer 10 X     10 ng 
- Quick solution     3 µμL 
- Primers forward     125 ng 
- Primers reverse     125 ng 
- dNTPs      1 µμL 
- dsDNA template     10ng 
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- PfuULTRA HF DNA polymerase (2.5 U/ µL)  1 µL 
 
Cycl
e 
Temperat
ure 
Time 
1 95°C 1’ 
 
18 
95°C 50” 
60°C 50” 
68°C 1’/Kb of 
plasmid 
1 68°C 7’ 
 
Digestion of the Amplification Products 
1 μL of the DpnI restriction enzyme (10U/µL) was added directly to each 
amplification reaction, then the reactions was immediately incubated at 37°C for 1 
hour to digest the parental supercoiled DNA.  
Transformation of DH5α competent cells and XL10-Gold Ultracompetent Cells 
DH5α bacterial cells were transformed to amplify the WT hMiRP containing 
plasmid. They were kept at -80°C and thaw on ice upon use. Then, the 10 ng of 
plasmid were added and incubated on ice for 30 minutes. Finally the cells were put 
at 42°C for 45 seconds and then on ice for 1 minute. They were then let to grow in 
900 μL of liquid LB medium at 37°C for 1 hour, before plating them on agar 
dishes containing the appropriate antibiotic for the plasmid vector. The dishes were 
incubated overnight at 37°C.  
XL10-Gold ultracompetent cells were used to transform the mutated plasmid 
treating them first with βME, then adding up to 10 ng of plasmid and incubating 
the reactions on ice for 30 minutes for each transformation. After a heat-pulse in a 
42°C water bath for 30 seconds, the tubes were incubated on ice for 2 minutes 
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adding next 500 µμL of preheated NZY+ broth and incubating the tubes at 37°C for 
1 hour with shaking at 250 rpm. Finally, the proper volume of reaction was plated 
on antibiotic-containing agar dishes, incubating the transformation  plates at 37°C 
for >16 hours.  
The day after the colonies were picked and let growing in liquid LB medium for 
another night. Subsequently, the plasmid DNA was extracted using NucleoSpin 
Plasmid Kit (Macherey-Nagel).   
The correct insertion of the desired mutation was then further confirmed by direct 
sequencing. 
Isolation of cortical neurons 
Cortical neurons were isolated from post-natal day 2 (P2) CD rat pups (Harlan 
Laboratories). Rats were anesthetized (isofluorane) and decapitated; then, brains 
were quickly removed and placed in ice-cold dissociation medium containing the 
following (in mM): 134 Na-isethionic acid, 23 glucose, 15 HEPES, 2 KCl, 4 MgCl2 , 
0.1 CaCl2 , and 10 kynurenic acid, pH 7.2. The cerebral cortex was isolated using 
fine tweezers, chopped into small pieces, and digested in a dissociation medium 
containing 1.3 mg/ml protease (type XIV; Sigma) for 20 min at 37°C in agitation. 
The tissue pieces were then rinsed twice in dissociation medium and mechanically 
dissociated using a series of progressively thinner fire-polished Pasteur pipettes. 
The dissociated neurons were plated onto poly-D-lysine-coated 35 mm dishes at a 
density of 1.5x106 cells in a solution of dissociation medium and culture medium. 
After 1 h at 37°C and 5% CO2, this solution was replaced with Neurobasal 
complete culture medium (see below).  
Transfection of heterologous system: CHO cells 
These cell are used because they present negligible expression of ion channels. 
They were grown in Hamster Nutrient, 10% FBS, 1,5 g/L NaHCO3, 2mM L-
glutamine, 1X PenStrep (Life Technologies). Cells were maintained in incubator at 
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37°C with 5% of CO2. One day before transfection cells were detached from the 
dish with trypsin and re-plated at a proper density in a 35mm plate. The 
experiment was carry out following standard protocol of 
FuGENE® HD Transfection Reagent (Promega®) using 3:1 ratio volume/weight. 
CHO cells were transfected with 1 μg of HCN2 or HCN4 alone or with 0,77 μg of 
hMiRP WT, M54T or both. For each transfection the transfection solution 
containing plasmidic DNA, Fugene HD in ratio 3:1 and medium without serum to 
100 μl was prepared and after 15 minutes, the transfection solution was added drop 
by drop into 35 mm dish with 900 μl of culture medium. After 8h into the 
incubator at 37°C the medium was removed and 2 mL of clean culture medium 
was added.  
Transfection of neonatal rat cortical neurons 
Cells plated onto poly-D-lysine-coated 35 mm dishes were grown in a soil with 
Neurobasal A culture medium (Life Technologies) supplemented with B27 (Life 
Technologies), 1 mM Glutamax-I (Life Technologies), 10 ng/ml β-FGF(Life 
Technologies), 50 U/ml penicillinG (Sigma), and 50 μg/ml streptomycin (Sigma). 
Cells colture were maintained in incubator at 37°C with 5% of CO2. After one day 
from isolation, cortical neurons were transfected following standard protocol of 
Lipofectamine™ 2000. 
For each dish Mix A was prepared in a polystyrene tube and Mix B in 1.5 mL 
tube; Mix A was at rest for 5 minutes, meanwhile Mix B was prepared. After 5 
minutes, Mix B was added in Mix A and after 20 minutes at room temperature in 
the dark, the transfection solution was added drop by drop in the 35 mm dish with 
900 μL of culture medium. After 24 hours into the incubator at 37°C the medium 
was removed and 2 mL of clean culture medium was added. 
Mix A: 7,5μL of Lipofectamine 2000 and OptiMEM (Life Technologies) to 250 μL 
Mix B: DNA and OptiMEM (Life Technologies) to 250 μL. 
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Different combination of plasmids was used, particularly 1 μg of channel (HCN2 
or HCN4) alone or with 0,77 μg of MiRP WT, M54T or both. We also transfected 
only 1 μg of empty vector (pIRES), hMiRP WT or M54T. 
Electrophysiology  
Functional analysis of M54T mutation both in CHO cells and neurons were carry 
out through patch clamp experiment. 48 hours after transfection, CHO cells were 
detached from dish using trypsin and re-plated in 35 mm dish at single cell dilution 
in order to evaluate the properties of the currents while the cortical neurons were 
not detached. Dishes were placed on the inversion microscope plane and cells 
were perfused with physiological solution. Particularly, CHO cells were perfused 
with an external solution to improve dissection of the Ih current containing the 
following (in mM): 110 NaCl, 0,5 MgCl2, 1,8 CaCl2, 5 Hepes NaOH, 30 KCl, 1 
BaCl2, 2 MnCl2, 0,1 NiCl, 0,2 Nifedipine, pH 7,4. Pipettes contained the following 
(in mM): 10 NaCl, 130 KCl, 1 EGTA, 5 HEPES-KOH, 0.5 MgCl2, 2 ATP (Na salt), 
0.1 GTP (Na salt), and 5 phosphocreatine, pH 7.2. Cortical neurons were 
superfused with an external solution containing the following (in mM): 129 NaCl, 
1.25 NaH2PO4, 1.8 MgSO4, 1.6 CaCl2, 3 KCl, 10 Na-HEPES, 35 glucose, pH 7.4. 
The pipette solution contained the following (in mM): 120 K-gluconate, 15 KCl, 2 
MgCl2, 0.2 EGTA, 20 phosphocreatine, 2 ATP-Na, 0.2 GTP-Na, 0.1 leupeptin, 10 
K-HEPES, pH 7.2. The borosilicate glass pipettes, once filled with intracellular 
solution, had a resistance between 5 and 10 M. GFP-expressing cells were 
selected for patch-clamp analysis. The study of the currents was carry out with 
patch clamp techniques in voltage clamp mode using whole-cell configuration. The 
study of the action potentials was carry out with patch clamp technique in current 
clamp mode using whole-cell configuration. In cortical neurons current-clamp 
recordings, the membrane potential was kept at -70 mV. All experiment were 
made at room temperature. 
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A specific software (Clampex 9.2, Axon Instruments®) generated the protocols 
(see protocol below) used for stimulating the cells.  
Analysis of Ih Current in single cells 
Activation curves of HCN channel-mediated current (Ih) were obtained from the 
analysis of current tails at -135 mV. The Boltzman equation was used to interpolate 
the activation curve. The holding potential is maintained to -35 mV; activation 
curves were recorded using potential steps from -35 mV to -135 mV followed by a 
step at -135 mV. Each steps of potential was applied as long as necessary to reach 
the steady state of the current at that specific potential. 
The time constants of activation and deactivation were obtained using mono-
exponential function: 
It = I∞ (1-e 
–t/τ) 
where τ is the time constant defined as the time necessary to raise 63% of the 
current at stationary state. Deactivation traces were recorded using potential steps 
between -75 mV and +25 mV preceded by a step at -135 mV in order to fully 
activate the Ih current.  
Density current was evaluated at each steps by the ratio between the current and 
the capacity of the cell in which the current was recorded. 
Comparison of all data was made with independent Student’s t test or one-way 
ANOVA followed by Fisher test for means comparison and significance level was 
set to p<0.05. 
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RESULTS 
Functional analysis of M54T MiRP1 mutation on HCN2 properties in 
heterolgous expression system 
Previous literature data showed an effect of M54T mutation on HCN2 in 
cardiomyocytes86. Here, in order to better dissect the effect of M54T MiRP1 
mutation on HCN channels, we co-transfected WT or mutated MiRP1 with HCN2 
channel in an heterologous system, the CHO cells. We also co-trasnfected HCN2 
with the same amount of WT and M54T MiRP1 to mimic the heterozygous 
condition. The plasmids encoding WT or mutated MiRP1 contained also the 
enhanced green fluorescent protein (EGFP) under an IRES region, so that cells 
expressing MiRP1 were recognizable. As a control, we also co-transfected HCN2 
with the pIRES2-EGFP empty vector. 48 hours after transfection, we recorded the 
HCN2 current in the EGFP-positive cells; Figure 32A shows representative 
normalized current traces recorded during application of hypepolarizing steps from 
-35 to -135 mV (holding potential -35 mV) in cells co-transfected with HCN2 and 
WT MiRP1 (HCN2+WT), M54T MiRP1 (HCN2+M54T) and both WT and M54T 
MiRP1 (HCN2+WT/M54T) or the empty vector (control). Voltage dependence, 
current density and kinetics of HCN2 were compared.  
Analyzing the tail currents at -135 mV, we derived the activation curve of HCN2 
that was then fitted to the Bolzmann equation to obtain the values of half-activation 
(V1/2) and of inverse slop factor (s). Single activation curves were used to calculate 
the mean activation curves displayed in figure 32B for control (white), HCN2+WT 
(black), HCN2+M54T (orange) or HCN2+WT/M54T (orange and black). All the 
activation curves resulted essentially overlapped (figure 1B) and indeed statistical 
analysis revealed no significant difference (p>0,05) in the values of the mean V1/2 or 
s (control: V1/2 = -76,1±2,4 mV, s = 9,1±0,8 mV, n = 10; HCN2+WT: V1/2  = -
79,2±2,6 mV, s = 8,7±0,5 mV, n = 16; HCN2+M54T: V1/2 = -75,4±1,8 mV, s = 
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8,6±0,6 mV, n = 23; HCN2+WT/M54T: V1/2 = -73,4±1,8 mV, s = 10,0±0,5 mV, n = 
23), demonstrating that the voltage dependence of HCN2 was not modified.   
We then evaluated whether M54T mutation could alter HCN2 current density. In 
figure 32C the mean current density against membrane voltages is plotted for 
control, HCN2+WT, HCN2+M54T or HCN2+WT/M54T transfected cells. Even in 
this case, no significant difference were observed among mean values according to 
one-way ANOVA and Fisher test (p>0,05). This demonstrates that the M54T 
mutation does not modify HCN2 expression at the plasma membrane.  
Finally, we compared the time constants (τ) of activation and deactivation of HCN2. 
These constants indicate the time necessary to reach the 63% of steady state current. 
They were obtained fitting with a mono-exponential function current traces 
recorded at different membrane voltages during  the activation and deactivation 
protocols. Figure 32D shows average time constants of activation and of 
deactivation as a function of voltage. We can observe a slower activation of HCN2 
at -85 mV and at -95 mV in cells co-transfected with HCN2 and M54T MiRP1 
compared to control, HCN2+WT or HCN2+WT/M54T. These differences were 
statistically significant (ANOVA, p<0,05). Mean τ value at -85 mV for 
HCN2+M54T was 1,67±0,25 s (n = 15), compared with 0,95±0,15 s for the control 
(n = 9), 1,11±0,20 s for HCN2+WT (n = 12) and 1,02±0,08 s for HCN2+WT/M54T 
(n = 14); τ at -95 mV were: 0,87±0,11 s for HCN2+M54T, 0,54±0,07 s for the 
control, 0,61±0,09 s for HCN2+WT and 0,57±0,04 s for HCN2+WT/M54T. A 
similar effect has been previously reported using cardiomyocytes86. We did not 
observe instead any significant difference in the activation time constants at other 
membrane voltages, nor in the time constants of deactivation (Figure 32D).  
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Figure 32: Effects of WT or M54T MiRP1 on the properties of HCN2 current expressed in CHO 
cells.  
(A) Representative normalized current traces recorded with hyperpolarization steps to the range of 
-35/ -135 mV (interval -10 mV) from a holding potential of -35 mV. Tail currents at -135 mV not 
shown. (B) Plots of mean activation curves of control (white), HCN2+WT (black), HCN2+M54T 
(orange) and HCN2+WT/M54T (orange and black). Lines are the best fitting by the Bolzmann 
equation. (C) Current intensities normalized to cell capacitance plotted against membrane voltages 
(I-V curves) for control (white), HCN2+WT (black), HCN2+M54T (orange) and 
HCN2+WT/M54T (orange and black). Points represent the mean (±S.E.M.) of current density for 
each cell. (D) Mean activation and deactivation time constant curves of control (white), 
HCN2+WT (black), HCN2+M54T (orange) and HCN2+WT/M54T (orange and black). Points 
represent the mean (±S.E.M.) of the τ calculated for each cell. Activation time constants are 
significantly different in HCN2+M54T at -95 and -85 mV (*p<0,05). 
Functional analysis of M54T MiRP1 mutation on HCN4 properties in 
heterolgous expression system 
M54T MiRP1 mutation has been previously assessed in cardiomyocytes also on 
HCN4 isoform. Thus, we evaluated the effect of M54T MiRP1 mutation in CHO 
cells performing the same co-transfection conditions as before, but using instead 
HCN4. Representative recording of HCN4 current for control (white), HCN4+WT 
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(black), HCN4+M54T (orange) and HCN4+WT/M54T (orange and black) are 
shown in Figure 33A. 
We compared the mean activation curve of HCN4 shown in figure 33B and found 
no differences in the mean V1/2 or s values (control: V1/2 = -69,6±2,0 mV, s = 
9,9±0,7, n = 5; HCN4+WT: V1/2  = -70,0±2,1 mV, s = 11,5±0,6, n = 7; 
HCN4+M54T: V1/2 = -70,6±1,8 mV, s = 12,5±0,5, n = 8; HCN4+WT/M54T: V1/2 = -
73,6±2,2 mV, s = 12,4±0,4, n = 9). This demonstrates that M54T mutation does not 
influence HCN4 voltage dependence.  
We then analyzed HCN4 current density, since literature data showed that it is 
decreased by 80% in the presence of the M54T mutation86, in cardiomyocytes. 
Conversely, in our cells we did not observe any significant difference in current 
densities (Figure 33C).  
Nathawe et al. have shown that also  activation kinetics86 were affected by the 
M54T MiRP1. Thus we analyzed both HCN4 activation and deactivation τ and 
found no difference in the activation kinetics (Figure 33D). A slower deactivation 
was however observed in cells expressing  HCN4+M54T, but only from -45 to -25 
mV.  
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Figure 33: Effects of WT or M54T MiRP1 on the properties of HCN4 current expressed in CHO 
cells. 
(A) Representative normalized current traces recorded with hyperpolarization steps to the range of 
-35/ -135 mV (interval -10 mV) from a holding potential of -35 mV. Tail currents at -135 mV not 
shown. (B) Plots of mean activation curves of control (white), HCN4+WT (black), HCN4+M54T 
(orange) and HCN4+WT/M54T (orange and black). Lines are the best fitting by the Bolzmann 
equation. (C) Current intensities normalized to cell capacitance plotted against membrane voltages 
(I-V curves) for control (white), HCN4+WT (black), HCN4+M54T (orange) and 
HCN4+WT/M54T (orange and black). Points represent the mean (±S.E.M.) of current density for 
each cell. (D) Mean activation and deactivation time constant curves of control (white), 
HCN4+WT (black), HCN4+M54T (orange) and HCN4+WT/M54T (orange and black). Points 
represent the mean (±S.E.M.) of the τ calculated for each cell. Deactivation time constants are 
significantly different in HCN4+M54T at -25, -35 and -45 mV (*p<0,05). 
Functional analysis of M54T MiRP1 mutation on HCN2 and HCN4 
expressed in neonatal rat cortical neurons 
Since it has been shown that the effect of MiRP186, as well as the biophysical 
properties of HCN channels95,  can vary depending on the cell type in which they 
are expressed, we decided to test a possible effect of the mutation on HCN 
channels in a neuronal context. We co-transfected  neonatal rat cortical neurons 
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with WT or mutated MiRP1 and HCN2 or HCN4. We still transfected HCN 
channels because neonatal neurons express only very low levels of endogenous Ih, 
as shown  in figure 34A (left, non transfected cell). Instead, for simplicity we did 
not include the co-transfections of HCN channel and WT/M54T MiRP1. 
From HCN2 current traces recorded (Figure 34A, right), we derived the activation 
curves. Since these neurons are particularly sensitive to strong membrane 
hyperpolarization we used a protocol of only 5 steps with hyperpolarizing step  in 
the range -35 to -115 mV to avoid cell death. The mean activation curves displayed 
in figure 34B confirm the results found in the heterologous system, showing no 
difference in the voltage dependence of HCN2 (control: V1/2  = -75,1±2,1 mV, s = 
6,4±1,6; WT: V1/2  = -73,6±2,6 mV, s = 8,1±0,90, n = 6; M54T: V1/2 = -76,0±2,2 mV, 
s = 8,5±0,4, n = 12).  
We then analyzed the activation time constants, since this HCN2 property was the 
only affected by the presence of the mutation in the heterologous system. Again, 
the results in neurons confirmed those previously obtained in CHO cells: as 
displayed in the plot of figure 34D, showing time constants against voltage, the 
time constants of activation were significantly slowed (p<0,05) in presence of the 
M54T MiRP1 at -85 mV (WT = 0,58±0,04 s, n = 4; M54T = 1,00±0,08 s, n = 7), but 
not at other voltages.  
Finally, we also analyzed HCN2 current density in the different conditions, but 
again we did not find any difference (Figure 34C), demonstrating that M54T 
MiRP1 mutation does not affect HCN2 expression also in this neuronal system. 
We also evaluated possible effects of M54T mutation on HCN4 channel properties 
in this neuronal context. Due to the slower activation of HCN4, the activation 
curve protocol required longer hyperpolarization, causing cell death in most of the 
cases. We then used only a single hyperpolarizing step to record the current 
density at -115 mV, since this feature was the one strongly reduced in the presence 
of M54T mutation in cardiomyocytes86. Again, we observed that neurons co-
transfected with HCN4 and WT MiRP1 had a current density of -16,7±3,4 pA/pF, 
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which was not significantly different from that of -13,9±3,2 pA/pF found in 
presence of M54T mutation.  
 
Figure 34: Effects of WT or M54T MiRP1 on the properties of HCN2 current expressed in 
neonatal rat cortical neurons. 
(A) Representative current traces recorded with hyperpolarization steps to the range of -35/-115 
mV (interval -20 mV) from a holding potential of -35 mV. Tail currents at -115 mV not shown. (B) 
Plots of mean activation curves of control (white), HCN2+WT (black) and HCN2+M54T (orange) 
neurons. Lines are the best fitting by the Bolzmann equation. (C) Current intensities normalized to 
cell capacitance plotted against membrane voltages (I-V curves) for HCN2+WT (black) and 
HCN2+M54T (orange) neurons. Points represent the mean (±S.E.M.) of current density for each 
cell. (D) Mean activation time constant curves of HCN2+WT (black) and HCN2+M54T (orange). 
Points represent the mean (±S.E.M.) of the τ calculated for each cell. Activation time constants are 
significantly different in HCN2+M54T at -85 mV (*p<0,05). 
Effects of WT or M54T MiRP1 on neuronal excitability 
M54T MiRP1 mutation did not produce relevant effects on HCN channel current 
in the neurons. However, we questioned whether it can cause some effects on 
neuronal excitability acting on other ion channels, since MiRP1 is a β-subunit also 
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of many potassium channels1,47,63,121. Previously in our laboratory, we observed 
that high density of HCN channel current (>5 pA/pF) caused a strong decrease in 
neuronal excitability. Since in the co-transfection experiments described before 
HCN channel current density was always higher than 5 pA/pF, the effect of MiRP1 
on excitability could not be clearly evaluated. 
We decided then to perform another set of experiments, transfecting only WT or 
mutated MiRP1 in rat neonatal cortical neurons. Also in this case we transfected 
the empty vector as a control. After 48 hours from transfection, we recorded the 
action potentials generated upon stimulation with depolarizing current steps of 
progressively higher amplitude (10-60 pA). Figure 35A shows representative 
examples of action potentials recorded upon current injection (10-50 pA) in 
neurons transfected with empty vector (control), WT MiRP1 (WT) or M54T 
MiRP1 (M54T). As evident in the sample traces, neurons transfected with the WT 
MiRP1 display an overall increased excitability compared to the neurons 
transfected with the empty vector. The subsequent analysis revealed that they 
present a two-fold decrease relative to the control of the threshold current 
necessary to trigger action potentials, as shown in the bar graph of figure 35B 
displaying the mean threshold currents. In addition, the generated action potentials 
have a higher firing rate in WT MiRP1 transfected neurons than in control neurons. 
Figure 35C shows the mean firing rate relative to the injected current for control 
(white), WT (black) and M54T (orange) neurons. Surprisingly, neurons transfected 
with the M54T MiRP1 exhibit instead an excitability similar to the control neurons 
and significantly lower than the WT MiRP1 transfected neurons, as demonstrated 
by both the higher threshold current (Figure 35B) and the reduced firing rate 
(Figure 35C).  
These results show that MiRP1 increases neuronal excitability and that M54T 
mutation reverts this function. The molecular partner of MiRP1 causing this effect 
remain to be investigated. Notably, the decreased neuronal excitability due to 
M54T MiRP1 mutation does not directly correlate with the epileptic phenotype, 
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which is caused by neuron hyperexcitability; however, due to the interplay 
between excitatory and inhibitory neurons in signal integration, it is difficult to 
predict an in vivo effect.  
 
Figure 35: Effect of WT or M54T MiRP1 on neuron excitability. 
(A) Sample voltage traces recorded during injection of 2.5 s,10 –50 pA depolarizing current steps 
into neonatal rat cortical neurons. All measurements were performed with resting voltage held at -
70 mV. (B) Bar graph of mean threshold current required to trigger action potential firing; values 
were 38,6±4,6 pA (n=7), 16,6±3,3 pA (n=6), 37,8±6,6 pA (n=9) for control, wt and m54t neurons, 
respectively. According to one-way ANOVA, wt threshold current was significantly slower than 
that of control or m54t. (C) Mean rate of firing recorded upon current injection. WT (black circles, 
n=6) are clearly less excitable than control (white circles, n=7) and M54T-expressing cells (orange 
circles, n=9). 
  
 
97 
 
DISCUSSION 
Epilepsy is a very common brain disorder in the human population and many 
affected patients (33%) do not respond to pharmacological treatments98. In 
idiopathic epilepsies protein dysfunctions causing the pathological phenotype are 
mostly due to genetic mutations64. Identifying and characterizing new mutations in 
this type of epileptic patients would be helpful both to better understand the cause 
of the disorder and to provide new targets for the pharmacological research.   
Many of the mutated proteins found in epileptic patients are ion channels, 
including HCN channels64. Despite the evidence in animal models clearly linking 
HCN channel dysfunctions to epilepsy15,65,108,116, few mutations of HCN channels 
have been identified in epileptic patients and have been functionally characterized 
for their epileptogenic effect25,28,85. Investigations concerning the screening for new 
mutations are ongoing during the recent years and can be helpful to clarify HCN 
channel contribution to the disorder.  
Our group has begun to screen 185 idiopathic epileptic patients, evaluating both 
HCN channels and accessory proteins that normally interact and modulate these 
channels. For example, it has been shown in a rat model of epilepsy a reduction in 
the interaction between TRIP8b (tetratricopeptide-repeat containing Rab8b) and 
HCN1, normally stabilizing its somato-dendritic expression114. 
MiRP1 is one of these HCN-interacting proteins. It has been initially defined as 
HCN channel β-subunit from in vitro studies in Xenopus oocytes132, then further 
studies analyzed its role on HCN channel modulation in other heterologous 
expression systems4,14,22 and in cardiomyocytes86,95. In these studies, MiRP1 is 
shown to modify HCN current density and kinetics. Besides, another study 
demonstrated that MiRP1 deletion in an animal model produces alteration of HCN 
channels in the brain, leading to an increased neuronal excitability131. 
Upon the genetic screening we performed here, we found the M54T MiRP1 
mutation in an epileptic patient and in her daughter, who presented febrile seizures 
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(Figure 25). This mutation involves the transmembrane region of the peptide, 
causing a change in aminoacid polarity. Because of the already mentioned 
evidence of functional interaction between MiRP1 and HCN channels (especially 
in the brain), the involvement of HCN channel alterations in the etiology of 
epilepsy and because of a previous work showing a reduction of HCN4 current 
caused by the M54T MiRP186, we considered this mutation a good candidate to be 
involved in the epileptogenesis.  
We firstly assessed the effect of the mutation on HCN channels in a heterologous 
system. We did not find any significant effect neither on HCN2 nor on HCN4 
currents exept for a mild slowing of activation time constants of HCN2 only at -85 
and -95 mV (Figure 32). Notably, a similar effect on HCN2 activation was seen also 
by Nathawe et al. in cardiomyocytes, at -65 and -75 mV86. We also found a slower 
deactivation of HCN4 (Figure 33). This was not observed before in cardiomyocytes, 
where they instead observed again a slower activation at -65 and -75 mV and 
importantly a strong decrease (80%) in the current density at -110 mV86, which we 
did not found in our system. The effect we observed on HCN channel time 
constants, since are relative to only limited membrane voltages, appears unlikely to 
cause the epileptic phenotype.  
Our in vitro data on heterologous system showing that the M54T MiRP1 mutation 
has no effect on HCN channels are then in contrast with previous data on 
cardiomyocytes. Nonetheless, the effect of MiRP1 on HCN channels is very 
controversial and appears strongly species and context dependent.  
Notably, no effect of human WT MiRP1 on human HCN channels was observed 
in Nathawe et al. work on transfected cardiomyocytes86, as well as in a previous 
work from our laboratory on transfected HEK cells4. Also in the study here 
presented, human HCN channel properties did not differ in cells co-transfected 
with HCN2 or HCN4 and the human WT MiRP1 compared to cells transfected 
with only HCN2 or HCN4 channel (Figure n. and n.). Thus, our data play against 
a possible role of MiRP1 as HCN channel β-subunit. Another possibility is that the 
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effect cannot be identifiable in our heterologous context and consequently neither 
can the effect of M54T mutation.  
Indeed, evidences from the literature show that the effects of MiRP1 on HCN 
channels can significantly vary depending on the cellular context in which it is 
expressed. For example, the work of Yu et al. showed that rat WT MiRP1 
increases current density and accelerates kinetics of activation of mouse HCN1 and 
HCN2, when expressed in Xenopus oocytes132. However, Decher et al. showed 
that human MiRP1 not only increases current density, but also shift negatively 
HCN4 activation curve; and conversely to what was shown in Xenopus oocytes, 
MiRP1 decelerates activation kinetics of the channel in CHO cells stably 
expressing HCN422. Subsequently, Qu et al. demonstrated instead that rat MiRP1 
co-transfected with mouse HCN2 in neonatal rat cardiomyocytes causes a 4-fold 
increase of current density and accelerates both activation and deactivation kinetics 
of HCN295. More recently, Brandt et al. analyzed the effect of MiRP1 on HCN 
channel in CHO cells, showing that current densities of all HCN isoforms were 
increased and their activation kinetics were accelerated14.  
To address the question of whether MiRP1 and its M54T mutation can affect HCN 
channel properties in a neuronal context, we co-transfected WT or mutated MiRP1 
with HCN2 or HCN4 in neonatal rat cortical neurons. These cells express minor 
levels of HCN channels and MiRP1, thus the endogenous rat protein cannot 
saturate the human proteins expressed via transfection.  
Even in this cell system, our data did not show any effect of the M54T mutation on 
HCN2 or HCN4 channel properties. We only found a deceleration in the 
activation kinetics of HCN2 at -85 mV (Figure 34), that again appears insufficient to 
trigger the epileptic phenotype. Moreover, although we tested a different and more 
context-specific cell system, again no differences were observed in presence of the 
WT MiRP1 compared to the condition transfected with only HCN2 (Figure 34). 
Taken together these results show that also in neuronal context neither WT nor 
M54T MiRP1 affect HCN channel properties. Notably, MiRP1 deletion was 
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demonstrated to alter Ih current properties in brain slices of adult mice, suggesting 
that MiRP1 is instead necessary for the correct HCN channel function131. Thus, the 
functional interaction of MiRP1 and HCN channels in neurons remains unclear. It 
is possible that the interaction is more complex than it seemed; for example it 
could be mediated by other proteins in vivo, or could be specific for a certain 
neuronal context, as the corticothalamic neurons.  
Given the lack of WT MiRP1 effect on HCN channels in all the used cell systems, 
it is not surprising that M54T mutation in turn does not produce any alteration. 
Nonetheless, Nathawe et al. previously found this same mutation to affect HCN 
channel properties in cardiomyocytes even in the absence of an effect of the WT 
MiRP186. They explained this discrepancy as a different interaction of MiRP1 with 
HCN channels depending on the cellular context, as already mentioned, but still 
without giving clear explanations on the possible underlying mechanism.  
We then reasoned that M54T MiRP1 mutation may be involved in the epileptic 
disorder by acting on other ion channels, such as HERG, which has been largely 
characterized to assemble with MiRP11,47,63,121, or other potassium or calcium 
channels48,62,103. To verify this hypothesis, we analyzed neuronal excitability in 
presence of WT or mutated MiRP1. Since the high expression of HCN channel 
itself was demonstrated to decrease neuron excitability28, for these experiments we 
transfected in neonatal rat cortical neurons only WT or mutated MiRP1. In this 
way the effect on excitability of HCN current was abolished, since endogenous Ih 
is small in these neurons.  
Unexpectedly, we found that neurons transfected with the mutated MiRP1 appear 
less excitable than neurons transfected with the WT MiRP1. More stimulation was 
necessary to induce the generation of action potentials in M54T-transfected 
neurons compared to the WT; in addition, upon current injection beyond 
threshold, M54T-transfected neurons had a slower firing rate compared to the WT 
(Figure 35). The excitability of M54T-transfected neurons was instead comparable 
to that of control neurons, transfected with the empty vector. Indeed the presence 
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of WT MiRP1 induced higher excitability, while this effect was reverted by the 
presence of M54T mutation.  
The effect observed goes in the opposite direction of MiRP1 loss-of-function shown 
on brain slices of MiRP1 KO mice, where an overall increase excitability was 
observed131.  Nevertheless, the effect of a point mutation is not really comparable 
with a deletion, particularly because the mutation can produce also a gain-of-
function. Moreover, in our case the effect is not strictly mediated by HCN channels 
as in the study on KO mice131. The possible mediators of this reduced neuron 
excitability caused by M54T MiRP1 remain still to be investigated.  
In conclusion, this study functionally characterized the M54T MiRP1 mutation, 
showing that it produces no effect on HCN2 and HCN4 channel properties in both 
heterologous and neuronal in vitro systems. This mutation appears however to 
cause a reduction of neuron excitability, possibly acting on other ion channels, 
which remain to be determined. The reduced excitability is anyway not 
compatible with the epileptic phenotype, which has been associated instead with 
increased neuron excitability64. In addition, very recently the screening on the 
mother of the epileptic patient revealed that she carries M54T mutation even if she 
is not affected by epilepsy and has never experienced epileptic seizures in her life. 
Thus, M54T MiRP1 mutation found in an epileptic patient resulted to be not 
involved in the generation of the disorder. 
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